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Page 31 - line 5: Should read - ".... availability of
calcium regardless of the agonist."
Page 51 - line 26: Should read - "The total area of the
ipsilateral auditory cortex was 33664 picture points."
Page 55 - Table 12: The title should read - "The
relationship between the CBF level and the cumulative 
area percent Change obtained by densitometer."
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"These tests assume that the blood flow data were normally 
distributed. Although this can never be certain from a 
small number of experiments, there is no indication that 
the distribution was skewed."
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region of the pons has markedly less binding sites of 
radiolabelled calcium antagonists."
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SUMMARY
Nimodipine (a dihydropyridine derivative) is one of a 
range of compounds which have been termed calcium antagonists, 
and whose pharmacological efficacy may result partly from an 
ability to inhibit the slow inward current of calcium ions in 
cell membranes. Nimodipine is a potent dilator of cerebral 
vessels in vitro and in situ, and this has stimulated interest 
in its effect on normal cerebral circulation and its use in 
cerebral ischaemia.
In the studies that form this thesis, I have examined 
several aspects of the effect of nimodipine on the cerebral 
circulatory responses in normal brain and in the presence of 
a well defined focal ischaemic lesion induced by occlusion of 
the middle cerebral artery (MCA).
The effect of the calcium antagonist, nimodipine, on 
local cerebral blood flow (CBF) in 31 regions of the CNS was
T14 Istudied with the CJ-iodoantipyrine autoradiographic tech­
nique in lightly anaesthetised, mechanically ventilated rats. 
Continuous intravenous infusion of nimodipine (1, 2 or 4 pg 
kg "Suin ^) produced a dose-dependent reduction in mean arter­
ial blood pressure (MABP) (reduced by 26 + 2% after 30 min of 
nimodipine, 4 pg kg ‘Snin ^) and a significant elevation in 
plasma glucose concentration (increased by 44 + 2% after 30 
min of nimodipine, 4 pg kg ^min ^). Local CBF was increased 
significantly during infusions of nimodipine (1 pg kg ^min ^) 
in 9 of the 31 regions examined, e.g., the parietal cortex 
(by 108%), sensory-motor cortex (by 132%), auditory cortex 
(by 78%), frontal cortex (by 65%). In contrast to the incr­
eases in CBF observed in forebrain regions, no significant
increases in CBF were observed during nimodipine infusion in 
regions of the lower brain stem, cerebellum and pons, or in 
myelinated fibre tracts. The proportionately greatest 
increases in local CBF were observed during infusion of the 
lowest dosage of nimodipine (1 pg kg”’^ min~'1'), suggesting 
either that this dosage provokes maximum cerebrovascular 
relaxation or that effects of increasing concentrations are 
counteracted by the concomitant systemic hypotension. The 
findings of this series of experiments emphasise that the 
dose must be regulated very carefully to avoid hypotension 
and hyperglycaemia; with calcium antagonists, correct dose 
selection may therefore be critical.
The effects of a continuous infusion of nimodipine (1 pg
kg ^min on local CBF and local cerebral glucose utilisation
(CGU) were studied using the quantitative autoradiographic 
[~14 1 |~14 "1
[_ CJ-iodoantipyrine and |_ CJ-2-deoxyglucose techniques in 34 
anatomically discrete regions of the brain in lightly restrained, 
conscious rats. The infusion of nimodipine at this concentrat­
ion produced only a small (8%) reduction in the MABP. The 
administration of nimodipine did not alter the rate of glucose 
utilisation in any of the regions examined. By contrast, in 
24 regions CBF was increased significantly by 39-84% from con­
trol levels, most notably the cerebral cortices, thalamus, 
hypothalamus, most extrapyramidal regions, and some components 
of the limbic system, such as the hippocampus (molecular layer) 
and amygdala. Nimodipine did not alter CBF in the four white 
matter regions examined (mean increase in CBF: 1%). In vehicle
treated animals there was an excellent correlation (p<0.01) 
between the local levels of CBF and glucose utilisation, with'
the ratio of flow to glucose use being ^ 1 . 5  ml pmol in each 
brain region. During nimodipine treatment there was a simi­
larly excellent correlation (p< 0.001) between local CBF and 
local CGU, but the median ratio between local flow and glu­
cose use increased to 2.5 ml pmol Thus, the relationship
between local CBF and local CGU was well maintained, but was 
reset towards a higher level of blood flow.
The effect of nimodipine (1 or 2 pg kg""^min pre- 
[14 ~1
treatment on local CBF (J_ CJ-iodoantipyrine autoradiography) 
in rats that had undergone MCA occlusion were investigated in 
anaesthetised animals. In control animals, marked reductions 
in local CBF were observed throughout the cerebral cortices 
ipsilateral to MCA occlusion: the visual cortex (by 61%),
auditory cortex (by 73%) and sensory-motor cortex (by 75%).
The level of blood flow was reduced massively (by 92%) in the 
caudate nucleus ipsilaterally when compared to the contralat­
eral side of the lesion. Nimodipine (1 pg kg ^min ^) pre­
treatment increased the local CBF significantly in 26 of 34 
regions of the contralateral hemisphere, particularly in the 
neocortical areas (range 76-96%; average 86%). The ipsi­
lateral reductions in the local CBF observed in vehicle groups 
were significantly less pronounced with nimodipine (1 pg kg  ^
min ^) pre-treatment. The main areas in which the reduction 
in flow was minimised were the cortical regions (visual cortex, 
auditory cortex, parietal cortex, sensory-motor cortex and 
frontal cortex). By contrast, there were no changes in the 
local CBF in the centre of ischaemic lesion such as the caud­
ate nucleus. To ensure that these measurements of CBF at 
predetermined neuroanatomically organised sites did not obscure
the analysis of the cerebrovascular actions of nimodipine, the 
autoradiograms were examined using a new approach to quantitat­
ive densitometry which involved analysis of the frequency dis­
tribution of CBF. This rigorous approach to densitometric 
analysis of the autoradiograms showed that nimodipine (1 jig kg-'*' 
min ■*■) pre-treatment reduced the amount of brain with low levels 
of CBF. For example, in animals receiving vehicle, the area of 
auditory cortex with CBF less than or equal to 25 ml lOOg ^min ^ 
was 10 + 2% (contralateral) and 20 + 3% (ipsilateral), and in 
nimodipine pre-treated groups the area of auditory cortex with 
CBF less than or equal to 25 ml lOOg ^min ^ was 8 + 1 %  (contra­
lateral) and 3 + 1 %  (ipsilateral). Furthermore, analysis also 
showed that this pattern of flow distribution was not changed 
by nimodipine; instead, its effect was to maintain flow at a 
higher level throughout the hemisphere, and the higher values 
in the territory of the occluded artery formed simply a part of 
this general effect.
-1 -1
Nimodipine (2 pg kg min ) pre-treatment increased the 
local CBF significantly in 10 cortical and subcortical areas of 
the brain when comparisons were made between the contralateral 
hemisphere with the data from control rats, e.g., auditory cor­
tex (by 37%), parietal cortex (by 48%) and hippocampus (by 44%). 
When the hemisphere ipsilateral to occlusion was studied, nimod­
ipine modified local CBF. The main areas in which the reduct­
ion in flow was minimised were the cortical regions, auditory 
and parietal cortices.
Neuropathological quantification of the ischaemic damage 
showed that nimodipine (1 pg kg ^-min "*■) pre-treatment reduced 
the volume and the extent of cellular damage in the periphery,
but not the core of the lesion. The effects of the adminis­
tration of nimodipine (1 pg kg ^min (initiated 5 min after 
occlusion of the MCA) upon the local CBF have been studied in 
anaesthetised rats. Nimodipine post-treatment did not alter 
the level of local CBF in any of the 35 neuroanatomically 
defined areas either ipsilateral or contralateral to the 
occluded vessels. The lack of CBF alterations when nimod­
ipine administration was initiated after occlusion of the MCA 
contrasted sharply with the elevations in CBF in the portions 
of the ischaemic hemisphere which occurred when nimodipine was 
administered before occlusion of the artery.
The results from this thesis represent a comprehensive 
description of the cerebrovascular effects of nimodipine in 
anaesthetised and conscious rats, and in a rat model of acute 
cerebral ischaemia.
PREFACE AND DECLARATION
This thesis deals with the effects of the calcium 
antagonist, nimodipine, upon various aspects of cerebrovasc­
ular responses in anaesthetised and conscious rats, and in 
rat models of focal ischaemic lesion.
The majority of the results of this thesis were obtained
i~14 1
using the quantifiable autoradiographic J C |-iodoantipyrine 
technique. The Methods section describes in some detail the 
potential errors related to the measurement of the level of 
cerebral blood flow.
This thesis was obtained from my own original studies, 
and has not been presented previously as a thesis in any form.
CHAPTER I
INTRODUCTION
1. Historical Perspective
1.1 Calcium and contractile activity of smooth muscle.
\
More than a century ago, Sidney Ringer called attention 
++
to the importance of Ca in the contractions of muscle in his 
work on the contractile activity of isolated heart in the frog 
(1883). Later, Alexander Sandow (1952) suggested that Ca++ 
may play a key role in the muscle contraction. He proposed, 
as a working hypothesis, that "an action potential or membrane 
depolarization of the muscle-fibre surface promotes the entrance 
of Ca++ into the myoplasm, and this in turn provokes further 
reactions leading to the appearance of mechanical activity".
Since that time, evidence has accumulated for this concept.
In fact, Ca++ is the principal physiological ion that when 
injected at a low concentration into the muscle fibres produces 
shortening (Heilbrunn and Wiercinski, 1947; Niedergerke, 1955; 
Caldwell and Walster, 1963). A large bulk of information from 
several studies supports the view that Ca++ is the prime regu­
lator of contraction-relaxation cycle in various types of muscles 
(Fatt and Katz, 1953; Hagiwara and Naka, 1964; Somlyo and Somlyo, 
1968; Ebashi, 1980; Stull and Sandford, 1981; Weeb and Bohr, 
1979; Tsien, 1983). In addition, the permeability of the cell 
membrane to calcium ion is of great importance for a variety of 
cellular functions such as secretion of neurotransmitters (Reuter, 
1979; Duncan, 1983; Kraynack et al. 1983; Reuter, 1983).
1.2 Discovery of calcium antagonists.
In the late 1960s and early 1970s, a new group of extreme­
ly potent calcium antagonists were synthetised. In cardiac
muscle during depolarisation, there is an initial fast current 
carried by Na and a subsequent slow current carried partly by 
calcium ion (Coraboeuf, 1978; Reuter, 1979). Calcium penetrat­
ing into the cells through the slow channel appears to play an 
important role in triggering muscle contraction (Bolton, 1979). 
Albrecht Fleckenstein (1964) demonstrated that a newly synthes­
ised coronary vasodilator mimicked the effects of simple with­
drawal of calcium from the medium bathing isolated heart tissues. 
Fleckenstein had repeated Ringer's work (1883), and showed that 
the new compound, verapamil, inhibited cardiac contractibility, 
an effect which is reversible by calcium coupling excitation to 
contraction in heart muscle. Based upon such studies in cardiac, 
and later upon additional experiments in vascular smooth muscle 
(Fleckenstein et al. 1972; Fleckenstein, 1977; Godfraind, 1981), 
Fleckenstein and his colleagues, in 1969, introduced the term 
"calcium antagonists" to describe the compounds.
2. Terminology and Classification
2.1 Terminology.
Compounds which inhibit the influx of extracellular 
calcium into cardiac and vascular smooth muscle form a new and 
expanding class of therapeutic agents. Although originally 
referred to as "calcium antagonists" (Fleckenstein et al. 1969), 
other synonyms have been used; "slow-channel blockers", "calcium 
channel blockers", "calcium entry blockers", "calcium blockers",
"calcium influx antagonists", and so forth (Godfraind and Dieu, 
1981; McCalden and Bevan, 1981; Vanhoutte, 1982; Janis et al. 
1983; Norman et al. 1983; Sewing and Hannemann, 1983; Smith, 
1983; Timmermans et al. 1983; Venter et al. 1983; Winquist 
and Baskin, 1983; Schwartz and Triggle, 1984). Furthermore, 
the term calcium antagonist has recently been used to describe 
compounds which inhibit contraction by effects upon intracellular 
calcium-dependent mechanisms; for example, trimethoxybenzoates 
or the methylenedioxyindene analogues (Rahwan et al. 1977, 1979; 
Plascik et al. 1978, 1979; Church and Zsoter, 1980; Rahwan, 
1983; Weishaar et al. 1983). However, the extension in the 
use of this term has been criticised (Henry, 1980; Spedding, 
1982; Kazda et al. 1983; Jones, 1984). It is highly likely, 
in view of their diverse chemical structure, that calcium antag­
onists possess different sites or cellular mechanisms of action. 
On the other hand, Fleckenstein (1982) argued that this is not 
a reason for abandoning the term calcium antagonist, which covers 
the therapeutic actions of these drugs more accurately than any 
of the alternative new names. In a strictly scientific sense 
these synonyms may be acceptable, but from a medical point of 
view they are misleading (Jones, 1984).
With the introduction of this new nomenclature, a re­
assessment of the pharmacological properties of these drugs is 
required so that a clear distinction can be made between the 
calcium antagonists and compounds which modify the effects of 
calcium ions at intracellular or other additional sites. For 
the sake of clear terminology in this thesis, the name "calcium 
antagonist" is used to describe drugs which inhibit the influx 
of extracellular calcium into the cell;
2.2 Classification of calcium antagonists.
The potency of calcium antagonist drugs upon cardiac and 
smooth muscle has been used to sublassify these compounds. 
According to Fleckenstein (1982), calcium antangonists can be 
subdivided into two groups:
1) Group A: substances of outstanding calcium 
antagonistic potency and specificity, such 
as nimodipine, nifedipine, niludipine, 
verapamil, D600 and diltiazem.
2) Group B: Substances such as prenylamine, 
fendiline, terodiline, perhexiline, and 
caroverine. These drugs have prominent 
calcium antagonistic properties, but do not 
reach the outstanding degree of specificity 
of Group A.
The assessment of calcium antagonist drugs in high-K+ 
depolarised intestinal smooth muscle (guinea pig taeniacoli) 
has also indicated that there are two main subtypes of drugs 
(Spedding, 1981, 1982).
A: The dihydropyridine class; for example,
nimodipine, nifedipine, verapamil and 
diltiazem.
B: Flunarizine, cinnarizine, fendiline and
pimozide.
These two main subdivisions agree with findings in vascular 
smooth muscle.
Recently, several studies have reported findings of the 
presence of H dihydropyridine (nimodipine or nitrendipine)
binding sites in the rat (Ehlert et al. 1982; Murphy and Snyder, 
1982; Murphy et al. 1983) and guinea pigs (Bellemann et al. 1981; 
Glossmann et al. 1982). The fact that there is excellent corre­
lation between the ability of various dihydropyridines to dis-
3
place specific H-nitrendipine binding and to inhibit mechanical 
activity in the cell preparations (Weiss, 1981) is consistent 
with a specific locus of action for these compounds. Glossmann 
et al. (1982) have characterised these binding sites and have 
reached the conclusion that three classes of compounds exist.
Class I: drugs which may possess a single binding
site, such as fendiline, tiapamid and flunarizine, 
in addition to related dihydropyridine compounds 
(nimodipine and nifedipine).
Class II: drugs which have been found to possess
multiple sites; for example, verapamil and D600.
Class III: drugs under the subdivisions of Class
3
II drugs and diltiazem which increase H-nimodipine 
binding (see also Ferry and Glossmann, 1982a,b).
It should be noted, however, that the grouping of flunar­
izine and fendiline with the dihydropyridine compounds is not 
consistent with the classification based pharmacological activ­
ity (Spedding, 1982) or the potency of the calcium antagonist 
drugs (Fleckenstein, 1982). This may be due to the possibility 
and flunarizine and fendiline are non-selective drugs and have 
additional cellular sites of action not detected by ligand and 
binding studies (Nakayama and Kusuya, 1980; Llenas and 
Massingham, 1983).
3. General Pharmacology
3.1 Pharmacology of calcium antagonists.
Calcium antagonists are a heterogeneous group of drugs 
which encompass structurally diverse compounds (Mizgala, 1983; 
Dipalmia, 1983; Singh, 1982, Nayler, 1983c). These drugs have 
different and variable effects on the contractibility of the 
myocardium and vascular smooth muscle (Fleckenstein, 1982).
An understanding of the pharmacokinetics of calcium 
antagonist drugs is essential in order to design appropriate 
dosage regimens which will provide optimum therapeutic efficacy. 
There are numerous studies regarding the kinetic of verapamil, 
diltiazem and nifedipine (Horster, 1975; Schlossmann et al. 
1975; Rovei et al. 1977; Eichelbaum et al. 1979; Rovei et 
al. 1980; Kates, 1983; Meyer et al. 1983; Talbert and Bussey, 
1983). Table 1 shows the major pharmacokinetic properties of 
these compounds. However, little is known about the pharmaco­
kinetics of nimodipine.
3.2 Pharmacology of nimodipine.
3.2.1 General.
The calcium antagonist, nimodipine, was developed in the 
late 1970s and early 1980s (Meyer et al. 1983). Since then, 
several studies in animal and man have been performed to invest­
igate its effect on vascular smooth muscle (Towart et al. 1981, 
1982; White et al. 1982; Kazda et al. 1979, 1980, 1982), and 
cerebral blood flow in normal and ischaemic brain (Harper et al. 
1981; Kazda et al. 1982; Gaab et al. 1982; Haws et al. 1983; 
Haws and Heistad, 1983, 1984; Steen et al. 1983; 1984; Smith
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et al. 1983). In these studies the dosages of nimodipine were 
variable with different schedules and route of administration.
As mentioned previously (see Section 3.1), it is important to 
know the pharmacokinetics of nimodipine to assess its thera­
peutic efficacy. Thus, it is essential to use an appropriate 
dosage and schedule of administration. Accordingly, the plasma 
level of nimodipine was calculated to relate the results of the 
present studies to other in vitro investigations and to in vivo 
studies that employed different modes of administration.
3.2.2 Nimodipine chemistry.
Nimodipine is a dihydropyridine derivative (1,4-dihydro- 
2, 6-dimethyl-4-(3-nitrophenyl)-3, 5-pyridine-dicarboxylic acid- 
isopropy1-(2-methoxy-ethy1)-ester) (Figure 1).
Nimodipine is a highly light-sensitive drug; thus, a 
special sodium vapour light is necessary during preparation of 
the drug.
3.2.3 Pharmacokinetic features of nimodipine.
Nimodipine is absorbed rapidly and completely after oral 
administration; the bio-availability of unchanged drug is 10% 
of the dose. The metabolites are excreted by renal and biliary 
routes. In rats, 80% of excretion is in the faeces and 20% in 
the urine. The half-life (tVz) of nimodipine is approximately 
20 minutes for rats. Binding to plasma protein in rats is 
96-98%. The distribution volume is approximately 0.7 L/kg for 
rats (personal communication, Dr. Kazda),
3.2.4 Concentration of nimodipine in the plasma.
When a drug is administered by continuous infusion
intravenously, the amount in the body will gradually increase 
to a plateau level ( M ) when the rate of elimination equals 
the rate of administration (Q). 
that is:
M = — =— (1) Bowman and Rand, 1980)
In 2
for nimodipine:
_.n . nv
m" = 2— MIn 2
where
m" is the plateau level of nimodipine, t11^  is the half-life 
of elimination for nimodipine, which is approximately 20 minutes 
for the rat.
n  —1
Q the rate of administration; for example, 1 pg kg min . 
Therefore,
Mn = 28.9 pg kg"*1.
Assuming 1 litre of blood equals approximately 1.05 kg (Sakurada 
et al. 1978), Mn = 27.5 pg L_1.
The molecular weight of nimodipine is 418.5.
—R
„n 27.5 x 10 ^  „
K = ' ~418.5~ = 66 nM-
The time reaches a given fraction (F) of plateau level is given by 
F = 1- e (t/t/£) in 2 (2) Bowman and Rand, 1980).
tn = L°ge (i-F) (3)
Loge2
where tn = time to reach the plateau for nimodipine.
Assuming F = 0.99 
.n 4.605 x 20 ,
t “ -57693 —  (4)
= 133 minutes.
For equation (4) a different level of (F) according to time per 
minute can be calculated (see Table 2» Figure 2). In the same
time the concentration of nimodipine in the plasma at different 
time per minute can be determined by equation (1,4) (see Figure 2).
3.2.5 Concentration of nimodipine in the CNS.
It has been estimated that the mean concentration level 
of nimodipine was 6.9 + 4.9 ng per millilitre in plasma and 
0.77 + 0.34 ng per millilitre in cerebrospinal fluid (Allen et 
al. 1983). In the rat, 96-98% of nimodipine is bound to pro­
tein in the plasma; the plasma concentration of nimodipine 
(1 pg kg ^min ^) at 60 minutes when infused intravenously was 
58 nM (see Figure 2). The free concentration of nimodipine 
will be 1.7 nM, and the approximate CNS level is 1.74 nM.
Andersson et al. (1983) suggested that the (the concen­
tration of drug required to produce 50% of relaxation) for 
nimodipine is 1.9 + 1.5 nM in the cat, which is approximately 
the same as the rat (Edvinsson, personal communication) which 
is very close to the level of nimodipine reached in the CNS 
(1.7 nM).
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Figure 2.
Time course of plasma concentration of Nimodipine
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4. Calcium Antagonists and Vascular Smooth Muscle
4.1 Calcium channels.
Vascular smooth muscle is a heterogeneous tissue and 
calcium movements during contractile process are complex (Bohr, 
1973; van Neuten and Vanhoutte, 1981; Gillis, 1982). The 
concentration of calcium which raises intracellular free Ca++ 
to initiate contraction depends on the nature of pharmacological 
stimulus (Winquist et al. 1981) and the phase of the actual con­
traction studies (Bohr, 1963; Sitrin and Bohr, 1971; Godfraind 
and Kaba, 1972; Godfraind, 1981). Bolton (1979) proposed an 
explanation for the calcium movement in vascular smooth muscle 
cells. He suggested that there are at least two different 
calcium channels in the cell membrane which permits the calcium 
to enter the cell.
1) The potential operated channel (POC), which is an 
ion channel population that opens as the potential 
across the membrane is reduced; for example, after 
K+-depolarisation.
2) The receptor operated calcium channel (ROC), 
which is an ion channel controlled or operated by 
the receptor for a particular stimulant substance; 
for example, noradrenaline.
4.2 Variability of sensitivity of POCs and ROCs to calcium 
antagonists.
The relaxant effect of calcium antagonists has been demon­
strated in many types of vascular smooth muscle (see Tables 3-7). 
The selectivity of calcium antagonists in different parts of the 
circulatory system appears to be related to differences in the
calcium sources and type of calcium channels used to mediate Ca 
influx (Toda, 1974; Golenhofen and Hermstein, 1975; Bolton,
1979; McCalden and Bevan, 1981).
Bohr (1963) divided responses of rabbit aorta to noradren­
aline into two components, an initial fast phasic response (Phase
I) and a later slow or tonic response (Phase II). The time 
course of the tonic response depended directly on the extracell- 
ular concentrations of Ca and was sensitive to calcium antag­
onists (Bevan et al. 1982). The concept that the POC is more 
sensitive to calcium antagonists than the ROC is supported by 
the findings that in most vascular tissues K-induced contract­
ions are more sensitive to calcium antagonists than noradrenal­
ine (NA)-induced contractions (see Tables 3-7).
In the rabbit aorta, K-induced contractions have been 
shown to be more sensitive to inhibition by the calcium antag­
onist, nisoldipine (Kazda et al. 1980), D600 (Schumann et al.
1975; Kazda et al. 1980), diltiazem (van Breemen et al. 1981), 
cinnarizine (Brockaert and Godfraind, 1979) and nifedipine 
(Schumann et al. 1975) than NA-induced contractions. Similar 
results have been obtained for D600 in rabbit mesenteric 
(Schumann et al. 1975), basilar and ear arteries (McCalden and 
Bevan, 1981); for diltiazem in rabbit renal artery (Bevan, 1982); 
for diltiazem and nifedipine in rat portal vein (Church and Zsoster, 
1980) and in the perfused rat mesenteric vascular bed (Kondo et al. 
1980); for cinnarizine (Brockaert and Godrained, 1979) and nisol­
dipine (Saida and van Breemen, 1983) in rabbit mesenteric artery; 
for nifedipine and flunarizine in rat mesenteric artery (Godfraind 
and Miller, 1982). Furthermore, contractions induced by prosta­
glandin (PGF2oc) in the human pial artery, and dog coronary
to inhibition by nifedipine (Brandt et al. 1981a), and verapamil
(Shimizu et al. 1980), respectively, that is activation by
depolarisation.
However, it may be argued that the ROC sensitivity to
calcium antagonists cannot be directly deduced from these
++results, since Na-induced Ca influx through the ROC may cause 
secondary membrane depolarisation and consequently POC activat­
ion (Cauvin et al. 1983).
In contrast, numerous investigations indicate that the 
ROC is more sensitive to calcium antagonists than the POC in 
certain vascular tissues (see Tables 3-7). Walus et al.
(1981) have shown that K+-contracted strips of isolated canine 
mesenteric arteries are less sensitive to nifedipine than are 
NA-contracted strips. Rat superior mesenteric arterial strips
-f
contracted with a K -depolarising solution are shown to have 
similar sensitivity to cinnarizine as compared with NA- 
contracted strips. Bevan (1982) has demonstrated that in 
the rabbit basilar artery NA-induced contractions are more 
sensitive to diltiazem than K -induced contractions, whereas 
they are about the same in the ear and mesenteric arteries. 
Verapamil is about equi-sensitive in inhibiting K+- and NA- 
induced contractions of the perfused mesenteric vascular bed 
of the rat (Kondo et al. 1980), and in inhibiting PGA,^ and 
K+-induced contraction of the dog cerebral artery (Shimizu et 
al. 1980).
Furthermore, Towart et al. (1981) suggested that the 
sensitivity of basilar artery in rabbit to the calcium antag­
onist, nimodipine, is equi-sensitive to 5-HT (5-hydroxytrypt-
amine) and K+-induced contraction, since the IC,.- for bothbU
vasoconstrictive substances was 2 x 10 ^M. They postulated
that the selectivity of nimodipine was due to blockade of the 
ROC in these vessels. Cauvin et al. (1982) have demonstrated
that diltiazem inhibition to NA and high K+-induced contractions
—8 —7
showed values of 1 x 10 and 6 x 10 M, respectively,
indicating that the ROC was more sensitive than POC to actions
of diltiazem.
In conclusion, calcium antagonists do not readily block 
ROCs that admit calcium, but do block the POCs (Bolton, 1979; 
Nayler and Pool-Wilson, 1981; Godfraind, 1981, 1982, 1983; 
Hogestatt et al. 1982; Bou et al. 1983; Nayler and Horowitz, 
1983; Andersson and Hogestatt, 1984). However, other studies 
suggested that calcium antagonists also may interfere with ROCs 
in certain vascular smooth tissues (Towart, 1981; Cauvin et al. 
1982; Bevan, 1982; Godfraind and Miller, 1982).
This variability in the concept of selectivity of calcium 
antagonists either on POCs or ROCs may be due to the following 
observations:-
1) There are regional as well as species variations in
sensitivity to calcium antagonists.
2) The variability of the calcium pool among vascular 
smooth muscles.
3) The potency of these drugs for inhibiting K or 
agonist-induced contractions varies widely in 
vascular smooth muscles.
4.3 Selectivity of calcium antagonists on cerebral
vascular smooth muscle.
Cerebrovascular smooth muscle differs from other periph­
eral vascular smooth muscle. Moreover, there is a marked
species variation in cerebral vessels (Duckies et al. 1977; 
Edvinsson and MacKenzie, 1977; Heistad et al. 1978). It 
follows that the consequences of calcium antagonists on vasc­
ular smooth muscle, either in vitro, and particularly in vivo, 
cannot be extrapolated from studies of other regional beds, 
even in the same species and certainly not between species 
(Bevan et al. 1982). This variability, however, may not 
exclude the possibility of considerable pharmacologic select­
ivity of calcium antagonist action on cerebral vessels.
Several comparative studies have shown that calcium antagonists 
attenuate the contraction of cerebral vessels provoked by a 
wide range of pharmacological (e.g., noradrenaline, serotonin, 
prostaglandin) and pathological stimuli (e.g., blood, cerebral 
ischaemia) (Hayashi and Toda, 1977; Allen and Banghart, 1979; 
Brandt et al. 1979, 1981a,b, 1983; Tanaka et al. 1980; Auer 
et al. 1981; Towart and Kazda, 1980; Auer et al. 1982, 1983; 
Hogestatt et al. 1982; White et al. 1982; Andersson et al.
1983).
Such selectivity has been described by Allen and Banghart 
(1979), who demonstrated the preferential action of nifedipine on 
cerebral vessels compared with femoral arteries of dog (see Table
4). Relaxations provoked by diltiazem in basilar artery were 
more sensitive to calcium antagonists than either mesenteric or 
the ear arteries of rabbit. Shimizu et al. (1980) have shown 
that the response of the dog basilar artery to prostaglandin 
was more sensitive to the vasodilatatory action of diltiazem, and 
of verapamil and nifedipine (see Tables 4 and 5). The topical 
application of nifedipine induces relaxation of feline cerebral 
arterioles that have been previously constricted by perivascular
injections of blood (Brandt et al. 1979). Nifedipine is more 
potent in relaxing the basilar than the facial artery (Hogestatt 
et al. 1982), and cerebral vessels were shown to be more sensit­
ive to NA- and K+-induced contraction than the ear artery in 
rabbit (McCalden and Bevan, 1981, 1982). Nimodipine is a 
potent calcium antagonist, and it has been shown to have greater 
effects on cerebral than peripheral arteries (Towart and Kazda, 
1979, 1980, 1982; Brandt et al. 1981a,b; Kazda and Towart, 
1981; Towart and Perzborn, 1981; Towart, 1982; Andersson et 
al. 1983).
Nimodipine and other calcium antagonists effectively 
inhibit the serotonin induced contractions of isolated rings 
of the rabbit basilar and saphenous arteries. The order of 
potency of the calcium antagonist drugs was nimodipine, nifed­
ipine, verapamil (Towart et al. 1982; Towart and Kazda, 1982). 
Andersson et al. (1983) demonstrated that the order of potency 
for the relaxation of human cerebral and mesenteric arteries of 
the various calcium antagonist drugs was nimodipine, nifedipine, 
verapamil and diltiazem.
White et al. (1982) demonstrated that nimodipine effect­
ively vasodilated the contractile responses induced in isolated 
canine basilar arteries by serotonin, prostaglandin 
thrombine and whole blood. Nimodipine was more potent than 
other dihydropyridine or non-dihydropyridine calcium antagon­
ists in relaxing the contractile activation induced by various 
stimuli. By contrast, Brandt et al. (1981a) showed that nifed­
ipine was more potent than nimodipine in relaxing human cerebral 
arteries contracted by potassium.
Cerebrovascular smooth muscle appears to be more sensit­
ive than other vessels to the action of calcium antagonists.
This may be due to the fact that the intracellular calcium 
pool is smaller in cerebral vessels than other vascular beds 
(Edvinsson et al. 1979; Bevan, 1981; McCalden and Bevan, 
1981; Towart et al. 1981; Cauvin et al. 1983; Bou et al.
1983).
TABLE 3.
EFFECT OF THE CALCIUM ANTAGONIST, NIMODIPINE,
ON VASCULAR SMOOTH MUSCLE.
m
Contractile
Species
Vessels
compared
activation, 
agent and 
the IC50
Reference
NA K+
Rabbit Aorta 3 x 10~5 
5HT
6 x 10"9 Towart et 
al. (1982)
Rabbit Basilar artery 2 x 10~10 2 x 10_1° Towart et
Saphenous artery 2 x 10~6 3 x 10"10
al. (1982)
Rabbit ,Basilar artery
txa2
—92 x 10
Towart and 
Perzborn
Saphenous artery 7 x 10“8 
PGF2 c<
(1981)
Human Pial artery 2 x 10-8 l\) X H-J O
1 CD Brandt et
Mesenteric artery
PGF2 oc
7 x 10”9
al. (1981a)
Cat Middle cerebral 
artery 3 x 10”9
_9
2 x 10 Andersson et
Mesenteric artery - 1 x 10“8
al (1983)
IC50 (concentration of the drug to produce 50% relaxation or inhibit­
ion of contraction, M); K+ (potassium); NA (noradrenaline); 5HT 
(5-hydroxytryptamine); TXA2 (Thromboxane A^); PGF^fprostaglandin).
TABLE 4.
EFFECT OF THE CALCIUM ANTAGONIST, NIFEDIPINE,
ON VASCULAR SMOOTH MUSCLE.
Contractile
Species
Vessels
compared
activation, 
agent and 
the IC50
Reference
NA K+
Human Mesenteric artery 2 x 10-6 1 x 10"7 Mikkelsen et
Mesenteric vein 3 x 10"6 
5HT
c*-10rHXI—1 al. (1978)
Dog Basilar artery 
Femoral artery
8 x 10“8 
5 x 10~7
NA
4 x 10~2
-2
5 x 10
Allen and 
Banghart 
(1979)
Dog Basilar artery 
Femoral artery
2 x 10~6
3 x 10”6
PGF
-
Allen and 
Banghart 
(1979)
Dog Cerebral artery 3 x 10“8 — Shimizu et
Mesenteric artery 5 x 10“7 
PGF2 oC
-
al. (1980)
Human Pial artery
CO1O
 
1—
1X
CM -97 x 10 Brandt et
Mesenteric artery
PGF2 oC
CO10HXCM al. (1981a)
Cat Middle cerebral 
artery 3 x 10“8 -97 x 10 Andersson et
Mesenteric artery
NA
2 x 10“8
al. (1983)
Rat Aorta 2 x 10~8
-9
1 x 10 Godfraind
Mesenteric artery 4 x 10""8
_ 9
2 x 10
(1982)
IC50 (concentration of the drug to produce 50% relaxation or
|
inhibition of contraction, M); K (potassium); NA (noradrenaline); 
5HT (5-hydroxytryptamine); PGF^^(prostaglandin).
TABLE 5.
EFFECT OF THE CALCIUM ANTAGONIST, VERAPAMIL,
ON VASCULAR SMOOTH MUSCLE.
Species
Vessels
compared
Contractile 
activation, 
agent and 
the IC50
Reference
NA K+
Human Mesenteric artery 
Mesenteric vein
3 x 10“6 
3 x 10"6
NA
3 x 10"6
4 x 10"6
Mikkelsen et 
al. (1978)
Rat Mesenteric bed 
Aorta
6 x 10 8 
4 x 10"6
PGF2 ©c
6 x 10”6 
3 x 10"7
Kondo et al.
(1980)
Massingham
(1973)
Dog Cerebral artery 
Coronary artery 
Mesenteric artery
1 x 10~7 
6 x 10"7
2 x 10"7
p g f2 <*
1 x 10“7 
3 x 10“7
2 x 10“7
Shimizu et 
al. (1980)
Cat Middle cerebral 
artery
Mesenteric artery
4 x 10”7 2 x 10”7 
5 x 10“7
Andersson et 
al. (1983)
IC50 (concentration of the drug to produce 50% relaxation or inhibition 
of contraction, M); K+ (potassium); NA (noradrenaline); PGF2oC 
(prostaglandin).
TABLE 6.
EFFECT OF THE CALCIUM ANTAGONIST, DILTIAZEM,
ON VASCULAR SMOOTH MUSCLE.
Species
Vessels
compared
Contractile 
activation, 
agent and 
the IC50
Reference
NA K+
-8 _7Rabbit Basilar artery 1 x 10
-6
1 x 10
-6
Bevan (1982)
Ear artery 1 x 10 2 x 10
NA
-7 -7
Rabbit Mesenteric artery 2 x 10
-7
6 x 10 Bevan (1982)
Saphenous vein 2 x 10
5HT
-8 -7
Rabbit Basilar artery 8 x 10 
, -7
1 x 10 
, -6
Bevan (1982)
Ear artery 8 x 10 2 x 10
NA
, -8 , -7 Cauvin et al.Rabbit Mesenteric artery 1 x 10 6 x 10 (1982)
p g f2<*
Cat Middle cerebral •7 p.
artery 4 x 10 1 x 10 Andersson et
_ -6 al. (1983)
Mesenteric artery 3 x 10
NA
-7 -7
Rabbit Mesenteric artery 5 x 10 6 x 10 Cauvin et al.
. 4 —7 (1984)Aorta 3 x 10 3 x 10
IC50 (concentration of the drug to produce 50% relaxation or inhibit­
ion of contraction, M); K+ (potassium); NA (noradrenaline); 5HT 
(5-hydroxytryptamine); PGF^^(prostaglandin).
TABLE 7.
EFFECT OF THE CALCIUM ANTAGONIST, D600,
ON VASCULAR SMOOTH MUSCLE.
Species
Vessels
compared
Contractile 
activation, 
agent and 
the IC50
Reference
NA K+
Q Q Massingham
Rat Aorta 7 x 10 2 x 10 (1973)
-5 -8 Schumann etRabbit Mesenteric artery 4 x 10 5 x 10 al. (1975)
*7 Van Breemen
Dog Coronary artery 1 x 10 1 x 10 and Siegel
(1980)
, -6 Meisheri et
Rabbit Aorta 6 x 10 1 x 10 al. (1981)
Rabbit Basilar artery 6 x 10~8 5 x 10“9 McCalden and
-7 _ -9 Bevan (1981)
Ear artery 6 x 10 4 x 10
5HT
%
Rabbit Basilar artery 3 x 10“8 McCalden and
, -7 Bevan (1981)
Ear artery 3 x 10
IC50 (concentration of the drug to produce 50% relaxation or inhibit- 
ion of contraction, M): K (potassium); NA (noradrenaline); 5HT
(5-hydroxytryptamine).
5. Ligand Binding Studies of Calcium Antagonists
Calcium antagonists can be labelled with
ine (Bellemann et al. 1981, 1982; Bolger et al. 1982, 1983; 
Ehlert et al. 1982; Gould et al. 1982; Murphy and Snyder,
Glossmann, 1982a; Glossmann et al. 1982, 1983a; Ferry et al.
High affinity binding sites for the dihydropyridine 
calcium antagonists have been recently described in various 
tissue membranes (see Tables 8 and 9), including brain, heart, 
vascular smooth muscle and skeletal muscle. The dihydropyrid­
ine derivatives interacted competitively and with high potency 
at the same receptor site (Ehlert et al. 1982; Janis and Triggle,
1984), whereas verapamil and D600 were somewhat less potent and 
interacted at a site distinct from the dihydropyridine binding 
site (Ehlert et al. 1982; Glossmann and Ferry, 1983a,b; Janis 
and Triggle, 1984). The non-dihydropyridine class of calcium 
antagonists do not compete directly at these sites, but do 
increase the dissociation rate of F^Hj-nitrendipine in cerebral 
cortex (Murphy et al. 1983); verapamil and prenylamine decrease 
p . ]  -binding, whereas diltiazem increases [3h] -binding (Ehlert 
et al. 1982; Depover et al. 1983; Glossmann et al. 1983a,b; 
Murphy et al. 1983).
Nimodipine, nitrendipine, nisoldipine and nifedipine are 
more potent in inhibiting the ^H^]-nitrendipine binding sites in 
brain and heart membranes than verapamil, D600 and diltiazem 
(Ehlert et al. 1982; Ferry et al. 1983a,b; Hoick et al. 1983;
1982), I ^HJ-nimodipine (Bellemann et al. 1982; Ferry and
1984), L HJ-nifedipine (Hoick et al. 1983; Pan et al. 1983),
M  -nisoldipine (Pan et al. 1983) and the calcium agonist 
^Hj Bay k 9644 (Janis et al. 1984a,b).
Peroutka and Allen, 1983). The relative potencies of various 
dihydropyridine agents in competing for binding sites (Bellemann 
et al. 1981; Bolger et al. 1982) parallel their pharmacological 
potencies (Henry, 1980; Fleckenstein, 1982).
Collectively, the radio ligand studies indicate the exist­
ence of high-affinity binding sites both for F^nJ-nimodipine and 
other agents of 1,4 dihydropyridines and for non-dihydropyridine 
calcium antagonists, in cardiac and vascular smooth muscle, 
skeletal muscle and brain. Furthermore, the radiolabelled 
ligand studies have been used to identify the calcium channels 
in various types of tissue. However, it should be noted that 
many of these studies were performed with homogenates from fully 
innervated organs, thus leaving the possibility open that nerve 
endings contribute to the overall binding. In experiments 
using rat brain it was observed that F^J-nitrendipine binding 
sites were localised to areas of the brain rich in synaptic 
connections and were largely confined to neural elements (Murphy 
and Snyder, 1982).
TABLE 8.
[3h]-nimodipine BINDING SITES TO TISSUE MEMBRANES.
Species Tissue Kd B Max Reference
Porcine Coronary
artery
1.5 0.10 Dompert and 
Traber (1984)
Porcine Pial
vessels
1.9 0.20 Dompert and 
Traber (1984)
Porcine Ventricle 1.4 0.18 Dompert and 
Traber (1984)
Rat Ventricle 0.25 0.39 Janis et al. 
(1982)
Guinea-pig Ventricle 0.35 0.4 Glossmann and 
Ferry (1983a)
Guinea-pig Skeletal
muscle
1.5 2.0 Ferry and 
Glossmann (1982a)
Guinea-pig Brain 0.3-0.4 0.3-0.35 Bellemann et al. 
(1982)
Rat Cerebral
cortex
1.1 0.50 Bellemann et al. 
(1983)
Guinea-pig Brain 0.4-0.8 0.60 Glossmann et al. 
(1983b)
Guinea-pig Brain 0.52 0.58 Glossmann and 
Ferry (1983a)
Human Brain 0.27 0.39 Peroutka and 
Allen (1983)
Kd (nM) represents the dissociation constant, and B max 
(pmol.mg ^ of protein) is the maximal number of sites.
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TABLE 9.
[3h]-nitrendipine BINDING SITES TO TISSUE MEMBRANES.
Species Tissue Kd B Max Reference
Bovine . Aorta 0.16 0.080 Sarmiento et 
al. (1984)
Canine Aorta 0.3 0.020 Triggle et al. 
(1982)
Rabbit Aorta 1.0 0.054 Bristow et al. 
(1982)
Porcine Coronary
artery
1.0 0.035 De Pover et 
al. (1982)
Canine Mesenteric
artery
0.25 0.025 Triggle et al. 
(1982)
Rat Mesenteric
artery
0.10 0.018 Triggle et al. 
(1982
Canine Atria 0.14 0.170 Sarmiento et 
al. (1982)
Canine Ventricle 0.30 1.5 Williams and 
Jones (1983)
Guinea-pig Ventricle 0.1 0.3 Bellemann et 
al. (1981)
Rabbit Ventricle 0.19 0.25 Janis et al. 
(1984b)
Guinea-pig Ventricle 0.16 0.213 Gould et al. 
(1983)
Rabbit Skeletal
muscle
0.75 3.18 Janis et al. 
(1984a)
Guinea-pig Skeletal
muscle
3.6 7.0 Ferry et al. 
(1983a)
Guinea-pig Skeletal
muscle
2.28 1.11 Gould et al. 
(1983)
Rabbit Skeletal
muscle
1.0 6.7 Fairhurst et 
al. (1983)
Kd (nM) represents the dissociation constant, and B max 
(pmol.mg ^ of protein) is the maximal number of sites.
6. Calcium Antagonists and Cardiovascular Circulation
In the last twenty years much work has been devoted to 
emphasising the effect of calcium antagonists on cardiovascular 
circulation. For example, verapamil (Sandler et al. 1968; 
Livesley et al. 1973; Andreasen et al. 1975; Rosing et al. 
1979a; Ferilinz, 1981) and nifedipine (Kobayashi et al. 1972; 
Ebner, 1975; Lorell et al. 1980) have been shown to be of 
clinical value in the treatment of angina pectoris. Both 
drugs increase exercise tolerance in patients suffering from 
angina pectoris (Previtali et al. 1980; Johnson et al. 1981). 
Verapamil (Rosing et al. 1979b) and nifedipine (Klugmann et al. 
1980) reduce blood pressure and total peripheral resistance, 
and it has been found that both drugs may increase coronary flow 
in the isolated perfused heart (Hashimoto et al. 1972; Refsum, 
1975). Recently, calcium antagonists represent a major thera­
peutic breakthrough in the treatment of various cardiovascular 
disorders; for example, angina (Theroux et al. 1983), atrial 
flutter and fibrillation (Brisse et al. 1982), hypertension 
(Buhler et al. 1983; Spivack et al. 1983), supraventricular 
tachycardia and ventricular tachyarhythmia (Singh et al. 1983). 
Furthermore, intensive studies on the effects of calcium antag­
onists on cardiovascular circulation proved that these drugs 
possess a great potential in the treatment of aortic insuffic­
iency (Fioretti et al. 1982), atherosclerosis (Henry, 1980, 
1982), cardioplegia (Clark et al. 1982), hypertensive emergency 
(Bertel et al. 1983), hypertrophic cardiomyopathy (Landmark et 
al. 1982; Spicer et al. 1983), migraine (Diamond and Schenbaum, 
1983; Kahan et al. 1983), and myocardial ischaemia and failure 
(Bellocci et al. 1982; Winniford et al. 1982).
7. The Effects of Calcium Antagonists on Cerebral
Circulation
The effects of calcium antagonists on the cerebral circ­
ulation in intact animals have not been clearly established. 
Various authors suggested that calcium antagonists prevent 
cerebral arterial constriction by affecting the intracellular 
availability of calcium, regardless the agonist. There is 
almost universal agreement that nimodipine and other calcium 
antagonists attenuate the contraction of cerebral vessels pro­
voked by a wide range of pharmacological (e.g., noradrenaline, 
serotonin, protaglandin) and pathological stimuli (e.g., 
blood, cerebral ischaemia) in vitro (Allen and Banghart, 1979; 
Towart and Kazda, 1979, 1982; Shimizu et al. 1980; Kazda and 
Towart, 1981; Towart and Perzborn, 1981; White et al. 1982; 
Andersson et al. 1983; van Neuten et al. 1983) and in vivo 
(Allen and Bahr, 1979; Cohen and Allen, 1980; Tanaka et al.
1980; Auer, 1981; Brandt et al. 1981b; Auer et al. 1982; 
Boisvert, 1983).
Several studies described marked elevations in CBF follow­
ing the administration of calcium antagonists (Harper et al. 1981; 
Kazda et al. 1982; Haws et al. 1983). Furthermore, some invest­
igators showed that calcium antagonists have a protective effect 
in several animal models of cerebral ischaemia (Hoffmeister et al. 
1979; Kazda et al. 1979; Steen et al. 1983). Allen and Bahr 
(1979) injected 2.5 ml of whole blood into the subarachnoid space 
in dogs and showed that the nifedipine (1 mg kg ^) pre-treatment 
effectively prevented the acute spasm. The results of this study 
were confirmed in patients by randomised, double-blind, placebo
controlled trial of nimodipine (Allen et al. 1983). One hundred 
and twenty five patients with intracranial aneurysm were treated 
within 96 hours of their subarachnoid haemorrhage, which was 
documented by CAT scanning or lumbar puncture. Overall, nimod­
ipine significantly reduced the occurrence of severe neurologic 
deficits due to spasm. It was felt that.the clinical efficacy 
of nimodipine was the result of its inhibition of cerebral arter­
ial spasm.
By contrast, several studies doubted the beneficial 
effect of calcium antagonists in preventing cerebral infarction 
(Harris et al. 1982), and others were unable to demonstrate any 
significant change in the CBF (Edvinsson et al. 1983; Newberg 
et al. 1984).
The level of cerebral oxidative metabolism is a crucial 
determinant of the level of CBF under normal circumstances 
(Kuschinsky and Wahl, 1978; McCulloch, 1982), and the effects 
of many pharmacological agents on cerebral metabolism may be 
the cause of changes in CBF rather than a direct action of 
the agent on cerebral vessels (Edvinsson and MacKenzie, 1977; 
Kuschinsky and Wahl, 1978). D'Avella et al. (1984) have 
studied the effect of the calcium antagonist on the cerebral 
metabolism and found that nimodipine increased glucose use 
in all brain regions. However, global cerebral oxygen con­
sumption did not appear to be altered during nimodipine admin­
istration in the studies of Harper et al. (1981); Haws et al. 
(1983); Steen et al. (1983); McCalden et al. (1984). On 
the other hand, the recent demonstrations of highly specific 
dihydropyridine binding sites in the brain (Bellemann et al.
1982, 1983; Ferry and Glossmann, 1982a,b; Quirion, 1983) and
the behavioural alterations after the administration of calcium 
antagonists (Hoffmeister et al. 1982; Shah et al. 1983), indi­
cate that nimodipine could act on cerebral tissue itself in 
addition to any actions it may exert on cerebral vessels.
8. Vasodilators and Calcium Antagonists in the Treatment
of Cerebral Ischaemia
Stroke is defined (World Health Organisation (WHO) as 
recommended by Marquardsen, 1978) as a rapidly developed sign 
of focal (or global) disturbance of cerebral function, leading 
to death, or lasting more than 24 hours, with no apparent cause 
other than vascular origin. A similar definition for stroke 
was adopted by the Royal College of Physicians (RCP) working 
group on stroke (1974).
The yearly incidency of stroke is approximately 2 per
2,000 per year for all ages (Kurtzke, 1976). Harris et al. 
(1971) found that stroke is the commonest cause of severe phys­
ical disability, and estimated that up to 130,000 people living 
at home in the United Kingdom are handicapped to some degree by 
stroke.
Various therapeutic regimens have been suggested to pro­
tect the brain during an ischaemic insult. Two main approaches 
have been explored in attempts to alleviate the consequences of 
cerebral ischaemia; in one, the primary target is the neuron 
itself; in the other, the aim is primarily to influence cere­
bral blood flow (CBF). Thus, the outcome of an ischaemic 
insult may be improved by increasing the tolerance of neuronal 
cells to ischaemic insult, or by the prevention of CBF falling 
below a critical threshold. Each mechanism may be influenced
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by calcium antagonists. Calcium is involved in the evolution 
of irreversible damage at the cellular level, and in vasomotor 
events in cerebral vessels (Siesjo, 1981, 1984).
It has been observed that barbiturates decreased the 
metabolic rate of oxygen consumption (CMRO^), and reduced 
significantly the size of infarcts in dogs following middle 
cerebral artery occlusion (Smith et al. 1974; Molinari et al. 
1976; Smith and Marque, 1976; Simeone et al. 1979). However, 
Black et al. (1978) showed that barbiturates decreased the size 
of infarcts, but increased mortality because of cardiac insuffic­
iency. Controlled clinical studies of barbiturate treatment of 
a variety of disorders are in progress, but preliminary results 
are not encouraging.
Therapies of cerebral ischaemia:
A. Therapeutics proposed to increase the brain's
ischaemic tolerance.
Metabolic depressants (e.g., hypothermia and barbiturates) 
have been investigated as a measure for protecting the brain from 
ischaemic damage. Hypothermia has been shown to reduce the 
cerebral metabolic rate of oxygen consumption (Smith and Wollman, 
1972). Michenfelder (1977) studied the effect of prolonged hypo­
thermia on MCA occlusion in monkeys and found that all treated 
monkeys died with infarction and cerebral oedema. He concluded 
that hypothermia induced an elevation in the blood viscosity, 
and that was responsible for the poor outcome. Furthermore, 
ischaemic brain damage is little influenced by this approach 
(Bloink et al. 1979).
B. Therapies proposed to improve blood flow.
1. Hypertension.
The loss of autoregulation in an ischaemic territory 
suggests that flow improvement should be possible through an 
increase in systemic blood pressure. Hope et al. (1977) 
observed an amelioration of neurological function by inducing 
hypertension, but there was evidence of an aggravation of 
brain oedema when blood pressure was increased (Fenske et al. 
1978). Nevertheless, this treatment is now widely used for 
ischaemia after operation for a cerebral arterial aneurysm.
2. Haemodilution.
Infusion of dextran or albumin resulted in significant 
increases in blood flow (Sundt and Waltz, 1967; Crowell and 
Olsson, 1972; Bloink et al. 1979). However, the flow increase 
is only temporary (Sundtand Waltz, 1967) and haemodilution 
decreases the oxygen binding to the blood, and this may be the 
reason why haemodilution failed to prevent the development of 
cerebral oedema in ischaemic brain (Bloink et al. 1979).
3. Anti-oedema agents.
Osmotic agents (e.g., glycerol, sorbitol or mannitol) 
have been investigated as means of measuring the development 
of brain's oedema in ischaemia (Bloink et al. 1979; Little 
and 0 1Shaughnessy, 1979; Bremer et al. 1980). Little (1978) 
observed that mannitol improved neurological function and reduced 
infarct size in cats after MCA occlusion. Furthermore, in a 
double-blind clinical trial glycerol administration effectively
decreased oedema in acute cerebral ischaemia (Mathew, 1972; 
Lassen et al. 1976). However, improvement of flow is only 
temporary, and there is no influence on the electrolyte shifts 
associated with oedema (Hossmann, 1983). Treatment of oedema 
has been attempted using corticosteroids. Some authors obser­
ved certain improvement of oedema (Fenske et al. 1979; Bremer 
et al. 1980), but others failed to demonstrate an ameliorating 
effect (de la Torre and Surgeon, 1976; Little, 1978).
4. Vasodilators.
Cerebral vasodilation can be achieved either by hyper-
capnia or the administration of drugs capable of inducing
cerebrovascular relaxation. Vasodilator therapy may have 
different mechanisms of action in the presence of focal 
ischaemic damage.
I. An improvement in CBF throughout the brain - including
the lesion.
This can be achieved when the vasodilator agent produces 
elevation in total flow in the hemisphere. Thus, more blood 
will be delivered to the ischaemic areas of the brain, even if 
the latter remains within the same percent of total hemispheric 
blood flow.
II. Deleterious redistribution of the CBF.
In these circumstances, the total hemispheric blood flow 
may not be unchanged. However, vasodilation occurs preferent­
ially in normal regions of the brain. This will result in 
these receiving an increased percent of hemispheric blood flow
compared to that of ischaemic regions of the brain in which 
1CBF will fall (steal phenomenon).
III. Beneficial redistribution of the CBF.
Again there may not be an alteration of total blood flow 
in the hemisphere, but preferential vasodilation occurs in the 
ischaemic territories and collateral supply. Thus, flow in 
this area increases at the expense of the rest of the hemisphere 
(Robin Hood syndrome).
The demonstration of Kety and Schmidt (1948) that 7% of 
CO^ in inspired air increased cerebral blood flow led to studies 
of the possibility that CO^ may contribute to the treatment of 
cerebrovascular disease. Furthermore, the capacity of pharma­
cological vasodilators to produce relaxation of cerebral vessels, 
and to improve the blood flow in normal and ischaemic brain, has 
been extensively studied (Lassen, 1959; Fazekas and Alman, 1965; 
Rosenblum, 1965; Regli et al. 1971a,b). Papaverine, aminophyll-
ine, hexobendine and numerous other vasodilating agents have been 
tested. However, few of these resulted in a consistent improve­
ment of cerebral blood flow (Regli et al. 1971a; Berry et al. 
1975; Bloink, 1979; Bartholini et al. 1980). Several authors 
have tested the possibility of increasing local cerebral perfus­
ion in the presence of an ischaemic lesion, and the agents used 
included the potent physiological stimuli, hypercapnia (Shalit 
et al. 1967; Symon et al. 1971; Yamaguchi et al. 1971;
Harrington et al. 1972) or hypocapnia (Battistini et al. 1971; 
Soloway et al. 1971; Harrington and DiChiro, 1973). Hypercapnia 
is assumed to improve the collateral circulation of the ischaemic 
tissues, and hypocapnia to induce vasoconstriction in the
non-ischaemic brain tissue, which might then improve the blood 
flow to the ischaemic territory by "reverse steal". The 
results were unsatisfactory; some authors observed that 
infarcts were smallest when CO^ was kept as close as possible 
to normal value without any deviation toward hyper- or hypo­
capnia (Harrington and DiChiro, 1973).
It has been argued that when focal ischaemic damage is 
present, a drug that acts as a direct cerebral vasodilator 
could reduce the vascular resistance in non-ischaemic, healthy 
brain tissue, but not in the ischaemic territory because the 
vessels in the damaged region are already dilated. The conse­
quences then would be an intracerebral steal with, at best, 
little improvement in the ischaemic territory and with the 
possibility of further reductions in CBF (Berry et al. 1975; 
Wilkins, 1980; Young et al. 1982, 1983; Hossmann, 1982).
Waltz (1971) wrote: "Present evidence provides no support
for the use of vasodilators in the treatment of acute cerebral 
ischaemia". However, McHenry (1972), discussing the use of 
cerebral vasodilators in cerebral infarction, stated: "One
can not accept the pessimism that there is no hope from more 
thorough evaluation and more aggressive management of the acute 
stroke".
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The use of drugs to inhibit Ca entry during cell 
ischaemia and to induce vasodilatation of the cerebral vessels 
is a more recent approach. The extracellular Ca++ is approxim-
_3 ++
ately in the millimolar (10 ) range, intracellular Ca is
—7 ++
approximately 10 M (Bohr, 1973). This Ca concentration
gradient is maintained probably by the cell membrane (Hagiwara
and Byerly, 1981; Tsien, 1983) which has a low permeability to
charged molecule and ions, and by an effective pump system that
maintains the Ca concentration at these low intracellular 
levels (Fabitor, 1983). A high level of permeability of cell 
membrane to calcium, and resulting dissipation of the Ca 
gradient, may lead to cell death (Fleckenstein et al. 1964; 
Hearse et al. 1977). Thus, massive influx of extracellular 
calcium into cell may initiate or represent a "Final Common 
Pathway" for cell death (Schanne et al. 1979; Farber, 1981). 
Calcium overloading may be involved in the pathophysiological 
processes of neuronal tissue damage (Harris et al. 1981; Hass, 
1981). Thus, it has been shown that the extracellular calcium 
decreases during ischaemia, and spreading depression is presumed 
to be due to translocation of Ca++ into the intracellular com­
partments (Hansen, 1981; Harris et al. 1981; Siemkowicz and
+ -f*
Hansen, 1981). An increase in the intracellular Ca is a 
prerequisite for cell death, as has been proposed for liver 
(Schanne et al. 1979), heart (Fleckenstein, 1977; Katz and 
Reuter, 1979; Nayler, 1983a,b) and cerebral tissue (Harris et 
al. 1981; Siesjo, 1981, 1984; Wieloch and Siesjo, 1982). It 
has been suggested that the influx of Ca++ into damaged tissue 
is due to disintegration of cell membranes, so that ions pass
freely into the cell (Happel et al. 1981). This increase in
++ ++Ca activity may arise both from the release of Ca from
intracellular stores, or by influx from extracellular fluid
(Peterson and Leblanc, 1976; Siesjo, 1984).
Several studies have found increases in cerebral Ca 
level in conditions of brain damage, e.g., in brains of mice 
exposed to cold stress (Korf et al. 1983), in the hippocampus 
during bicuculline or L-allylglycine induced seizures (Griffiths 
et al. 1982, 1983) and mechanically damaged spinal cord (Happel 
et al. 1981). There is extensive evidence that serotonin,
prostaglandins and noradrenaline may be the spasmogenic agents 
responsible for cerebral vessels constricting in the presence of 
blood in the subarachnoid space (Pennink et al. 1972; Allen et 
al. 1974; Starling et al. 1975; Boullin et al. 1976). All 
these substances act by increasing the concentration of intra­
cellular free calcium, thereby promoting cerebrovascular smooth 
muscle cell contraction (Allen et al. 1974; Towart et al. 1981). 
The observation that vasoconstriction occurs in an area of focal 
ischaemia (Waltz and Sundt, 1967) raises the possibility that 
Ca++ antagonists might affect this, and therefore improve local 
CBF.
9. The Aims of the Studies.
In the present studies, the effects of intravenous 
administration of various concentrations of nimodipine on local 
CBF in normal, anaesthetised rats were examined, and focussed 
particularly on the extent to which either regional hetero­
geneity in the cerebral circulatory responses to nimodipine 
or changes in arterial blood pressure may have contributed to 
previous inconsistent data on the effect of calcium antagonists 
,on cerebral tissue perfusion.
In an attempt to examine the functional significance of 
receptors for nimodipine present within the central nervous 
system (CNS), the effects of nimodipine on local cerebral glu­
cose phosphorylation were studied in conscious, normal rats.
/
Furthermore, in a parallel series of investigations, the effects
of nimodipine on local CBF were examined, and compared and con-
({
trasted with the actions of nimodipine on local cerebral glucose 
utilisation.
In addition, a series of experiments were performed to 
determine if nimodipine; reduced circulatory or pathological 
consequences of a well defined focal ischaemic lesion induced 
by occlusion of the middle cerebral artery.
CHAPTER II
MATERIALS AND METHODS
1. General
1.1 General surgical preparation.
A. Anaesthetised animals:
Experiments were performed with male Sprague-Dawley rats 
weighing between 300-470g. For the purpose of surgical prepar­
ation the animals were placed in a perspex box, when an anaes­
thetic gas mixture (70% nitrous oxide, 30% oxygen, containing 
5% halothane) was given. Anaesthesia was maintained by means 
of a face mask by which a 1% halothane mixture was delivered.
The animals were then tracheotomised, and mechanical ventilat-. 
ion (Sterling pump) with 0.5%halothane and N^O - 0^ (70% - 30%) 
was used.
Small incisions (approximately 1 cm) were made in both 
groins. The femoral vessels were exposed and polyethylene 
catheters, 15 cm long and filled with heparinised saline solut­
ion (10 iu/ml), were introduced retrogradely into both femoral 
arteries and veins for continuous measurement of arterial blood 
pressure, withdrawal of arterial blood (for blood gas measure­
ments), blood plasma glucose and blood sampling, and for admin­
istration of drug and tracer. The blood pressure was recorded 
by means of a Gould blood pressure transducer, blood gas measure­
ments were performed using a Corning 168 pH/blood gas analyser, 
and the plasma glucose was measured using a Beckman glucose 
analyser.
At least 30 minutes were allowed to elapse before giving
the drug to achieve stability of arterial blood pressure, plasma 
glucose and blood gases. Normocapnia was maintained by adjust­
ments in the tidal volume. Body temperature was maintained at 
37 + 0.5°C by keeping the animals on an automated heating box.
B. Conscious animals;
After inserting cannulae into both femoral arteries and 
veins, the cannulae and wounds were covered with local anaes­
thetic cream before closing the wounds with sutures. The 
wounds were covered with gauze pads, and plaster of paris band­
age (Gypsona, width 7.5 cm) was placed around the lower abdomen, 
pelvis and upper third of thighs. The plaster and feet were 
taped to a :lead weight to achieve immobilisation of the lower 
parts of the animal. Anaesthesia was then discontinued, and 
over two hours elapsed before starting the experiments. Body 
temperature was maintained at 37 + 0.5°C by external heating.
1.2 Technique of middle cerebral artery occlusion in the rat.
The middle cerebral artery was occluded according to Tamura 
et al. (1981a). With the animal in the semi-prone position, left 
side uppermost, a 2 cm skin incision was made vertically between 
the orbit and the external auditory canal. The temporalis muscle 
was separated from the superior temporal line, and the tissue plane 
between the orbital fascia and the temporalis fascia was exposed 
to the temporal bone. The temporalis muscle was then retracted 
posteriorly and the orbital contents anteriorly, using curved 
self-retaining retractors. The infratemporal fossa was exposed 
and the mandibular nerve identified. A craniectomy was made 
using a dental drill 3 mm anterior and 1 mm lateral to foramen 
ovale. The dura was opened with a fine needle, and the middle 
cerebral artery identified running across the edge of the
olfactory tract. The arachnoid was separated from the middle 
cerebral artery on each side, and a constant anterior branch 
running along the olfactory tract was found; a posterior branch, 
recurving proximally and giving deep lenticular striate branches, 
was also identified.
At the pre-designated time, the middle cerebral artery 
and these branches were occluded (Figure 3) using bipolar dia­
thermy (microbipolar coagulator, Downs Surgical). The main 
trunk of the middle cerebral artery was then divided to ensure 
discontinuity.
1.3 Drugs and tracers.
.Nimodipine solution was prepared freshly on the morning 
of each experiment. Because the breakdown of nimodipine is 
facilitated by white light, the drug was dispensed under sodium 
light; it was then added to a lutrol-glycerine-water mixture 
and heated gently with continuous stirring until fully dissolved. 
The drug, catheters and syringes for infusion were always covered
with silver foil. Nimodipine was obtained from Bayer, U.K.
Tl4 I fl4 "1
The isotopes used were C j-iodoantipyrine and [_ CJ-2-deoxy-
glucose (New England Nuclear, Boston, Massachusetts).
Figure 3.
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Middle cerebral artery and its branches as seen under the 
microscope, with the site of occlusion. (From Shigeno 
et al. 1985).
2. Measurement of Local Cerebral Blood Flow
Local cerebral blood flow was measured with the quantit-
14
ative autoradiographic technique with C-iodoantipyrine as a 
tracer, described by Sakurada et al. (1978).
1. Theory.
Kety and Schmidt (1948) demonstrated that Fick's princ­
iple can be utilised to measure blood flow. Fick's principle 
stated that the quantity of a substance taken up by an organ in 
a unit time equals the total amount of the substance brought to 
it by the venous blood for the same period. The equation 
derived by Kety and Schmidt (1948) and Kety (1951, 1960) for 
calculating local blood flow is based mainly on balance at the 
capillary level.
= F(Ca-Cv) (1)
where Ci is the tissue concentration, F the blood flow per gram 
of tissue and Ca and Cv the arterial and venous concentration 
of the tracer, respectively. Provided instantaneous diffusion 
equilibrium occurs between blood and tissue, the tissue and 
blood concentrations of the tracer are related through the 
partition coefficient (\), I.e.
Cv = Ci/ X  (2)
Inserting this into equation (1) gives a first order differential 
equation that Kety solved for condition of Ci (0) to get
Ci(T) = AK Cae-K(T-t) dt (3)
where Ci(T) equals the tissue concentration of the chemically
inert diffusible tracer in a homogeneous tissue at a given time, 
T, after the introduction of the tracer into the circulation;
Xequals the tissue; blood partition coefficient; Ca is the 
concentration of the tracer in the arterial blood; t equals 
the variable of time; and K is the constant that incorporates 
within it the rate of blood flow in tissue. The constant K 
is defined by Kety (1951) as follows:
K = mf/w X  (4)
where f/w equals the blood flow per unit mean of tissue and m 
equals a constant between 0 and 1 that represents the extent to 
which diffusion equilibrium between blood and tissue is achieved 
during passage from arterial to venous end of the capillary.
In the absence of diffusion limitation or arteriovenous shunt, 
m=l, and becomes inconsequential in the relationship between K 
and the perfusion rate of the tissue. The rate of blood flow 
can then be determined from the value for K calculated by the 
equation (3) from measured values of the tracer concentration 
in the tissue at a given time following the onset of circulat­
ion of the tracer, the history of arterial concentration of the 
tracer, and the tissue:blood partition coefficient.
2. Practice.
Rats were prepared according to the experimental design,
and local cerebral blood flow measurement was performed using
14
the diffusible tracer C-iodoantipyrine (50 pCi in 1.5 ml 
saline). The isotope was infused intravenously over a 30 
second period on a "ramp" schedule, i.e., the rate of infusion 
was increased progressively so that the arterial tracer concen­
tration would be highest at the end of the experiment. Thus, 
the possibility of reaching a steady-state arterial tracer 
concentration can be avoided, and brain regions with high or 
low blood flow can be distinguished. During administration
of the tracer, arterial blood was allowed to drip freely from 
a partially occluded catheter in the femoral artery, and 15-18 
samples of blood were taken separately on pre-weighed filter 
discs. The animals were sacrificed and the brains processed 
for quantitative autoradiography.
2.1 Liquid scintillation analysis.
The filter discs were quickly and tightly capped in 
scintillation vials to prevent evaporation, and re-weighed.
From the assumed specific gravity of whole blood (1.05)
(Sakurada et al. 1978) and the weight difference, the sample 
volume was calculated. Hydrogen peroxide (0.4 ml) and water 
(1 ml) were added to bleach the blood; thus, the possibility 
of colour quenching could be reduced. Vials were left at room
temperature for at least 2-3 hours to allow completion of bleach­
ing, and 10 mis of liquid scintillant (Picofluor) were then 
added. Twenty-four hours were allowed to elapse before liquid 
scintillation analysis. Each sample was counted for four min­
utes and the raw count data were converted to disintegrations 
per minute, using the external standard channels ratio method 
(Peng, 1977) together with a standard quench correction calib­
ration curve.
2.2 ' Preparation of autoradiograms from brain sections.
At the end of infusion of the isotope, the animal was 
decapitated and the brain was quickly dissected. The dorsal 
cranium was removed, the dura was divided vertically from the 
olfactory lobe to the medulla oblongata, and then reflected.
The whole brain was removed and frozen in isopentane, pre-cooled 
to -45°C. Decapitation and freezing of the brain were performed 
within 2-3 minutes to minimise the loss of resolution due to the
isotope diffusion. The frozen brain was embedded in tissue - 
Tek II (R.A. Lamb, London, U.K.). Brain sections (20 microns 
thick) were cut from the medulla oblongata to the prefrontal 
cortex in a cryostat (Bright, U.K.) at -22°C, and three in every 
20 sections were mounted on glass cover slips and dried on a 
hotplate (60°C). The cover slips were fixed into thin card­
board and (together with a set of plastic standard (^C) 
methylmethacrylate of known concentration (44-1475 nCi/g) 
which had been precalibrated for 20 um brain section) were 
applied to X-ray film (Kodak SB-5) for seven days in light­
tight cassettes.
2.3 Quantitative densitometric image analysis.
2.3.1 Standard measurement.
Analysis of the resultant images on the X-ray film was 
performed using a computer-based densitometer (Quantimet 720, 
Cambridge Instruments), with reference to the precalibrated 
standards. For each region of the brain, twelve optical read­
ings were made bilaterally on six consecutive sections in which 
the structure could be anatomically defined by reference to 
stereotactic atlases (Zeman and Innes, 1963; Konig and Klippel,
1963), and the mean optical density of these 12 measurements
14
was used to calculate C tissue concentrations. The areas
2
of measurement varied from 0.25 mm for large homogeneous reg­
ions of the CNS, such as hypothalamus and caudate nucleus, to 
0.02 mm for smaller brain areas such as substantia nigra (pars 
compacta) and hippocampus molecular layer. The size of the 
frame was maintained constant for the same region in different 
animals.
2.3.2 Frequency distribution analysis of the cerebral 
blood flow following MCA occlusion.
The use of conventional analysis of CBF (see 2.3.1) in
14
the ischaemic model, employing the C-iodoantipyrine autoradio­
graphic technique, has been studied previously (Tamura et al. 
1981b; Mohamed et al. 1983; Smith et al. 1983). In this 
method, selected neuroanatomically defined areas were measured. 
This approach may not fully assess the extent of changes in local 
CBF within or outside the territory of ischaemic cellular lesion. 
Therefore, frequency distribution of the CBF level was analysed
in some experiments in this thesis (see Effect of nimodipine,
-1 -11 pg kg min , on the CBF with MCA occlusion - page 122) in an 
effort to provide more reliable information about the CBF level 
in the centre and periphery of the ischaemic lesion. In this 
method of analysis, the optical densities corresponding to 
particular CBF values were calculated by reference to the pre­
calibrated standards on the film and the history of arterial 
tracer concentration. The distribution of blood flow was 
studied for the auditory cortex, parietal cortex, sensory-motor 
cortex and the caudate nucleus, ipsilateral and contralateral 
to the lesion. This was achieved by delineating the area 
examined (taken from three sections of autoradiograms of equal 
thickness) on the densitometer screen, using the image analyser 
and the densitometer function. The total delineated area was 
expressed by a picture point number obtained on the densitometer 
screen. Selected CBF levels at intervals of 25 ml lOOg ^min ^ 
were studied by dialling up the optical density which correspond­
ed to cumulative flow bins (0-25, 50-75, .....  175-200). The
area shown on the densitometer screen is represented by a picture 
point which has been recorded for each flow bin. The size of
area was then expressed as a percentage of total area. As an
example, the following steps were taken to measure the CBF in
the ipsilateral auditory cortex in a vehicle administration
after MCA occlusion.
Firstly, the arterial concentration of the tracer was
taken from the liquid scintillation analyser, together with
the weighed samples, and the corresponding recorded time was
entered into a computer (Cromenco System 3). The optical
14
density of the plastic C standards was measured by the 
densitometer. The computer then works out the best fit 
between the optical density (OD) and the known *^C concentrat­
ion (see Table 10). Secondly, using a computer programme
designed by Dr. W. Angerson, the calculation of the CBF was
14
determined for the C-iodoantipyrine method (Sakurada et al.
1978). By dialling various values for optical density we
obtained the corresponding CBF values (25,50,75 .... 200 ml 
- 1 - 1lOOg min ) (see Table 11). Thirdly, the ipsilateral audit­
ory cortex was then delineated by the electric bin and a picture 
point figure corresponding to the total area was recorded from 
the densitometer screen. The optical density matching the 
particular cumulative flow-bin was then dialled up, and the 
new picture point figure was recorded for each flow level.
The size of the area was expressed as a percentage of total 
area (see Table 12).
The total area of the ipsilateral auditory cortex was 
33664. Therefore, by this method we can analyse the extent
i
of ischaemic damage within and outside the lesion. From 
Table 12 we can see that 30% of the total area of the ipsi­
lateral auditory cortex had a CBF level equal or less than
25 ml lOOg ^min \  and 95.4% of the total area had a CBF equal 
or less than 100 ml lOOg ^min \
/
TABLE 10.
THE RELATIONSHIP BETWEEN STANDARD OPTICAL DENSITIES AND
THE CONCENTRATIONS OF THE ISOTOPES.
Standard
O.D.
Standard Concentration (nCi/g)
True Best Fit
0.042 44 43
0.073 70 70
0.159 179 181
0.212 271 270
0.298 450 444
0.330 509 515
0.446 793 792
TABLE 11.
THE RELATIONSHIP BETWEEN THE OPTICAL DENSITY VALUE AND 
THE CORRESPONDING LEVEL OF THE CBF.
O.D. CBF (ml lOOg ^niiT1)
0.124 25
0.203 50
0.262 75
0.308 100
0.350 125
0.385 150
0.418 175
0.447 200
TABLE 12.
THE RELATIONSHIP BETWEEN THE CBF LEVEL AND THE AREA 
PERCENT CHANGE OBTAINED BY DENSITOMETER.
CBF Level Area (Picture-Point Area % Change
0-25 23539 30
25-50 10930 67.5
50-75 3694 89
75-100 1543 95.4
100-125 317 99
125-150 59 99.8
150-175 0 100
175-200 0 100
i
3. Potential Errors Associated with Measurements 
of Local Cerebral Blood Flow.
In the present work the method, the performance and
factors that influence the accuracy of CBF values obtained 
14by the C-iodoantipyrine autoradiographic technique were 
examined. These factors include:
3.1 The accuracy of estimation of kill-time.
The kill-time is the time measured from the end of the 
isotope i n f u s i o n ;to the completion of decapitation.
3.2 The accuracy of the catheter lag-time correction.
The concentration of tracer in the cerebral arterial
blood at any time is assumed to be equivalent to that in the 
abdominal aorta (i.e., at the catheter tip). The concentrat­
ion of the tracer sampled from the catheter is delayed relative 
to that in the brain by the amount of time it takes the blood 
to flow through the catheter (lag-time). This lag-time 
correction, which varies from animal to animal, is determined 
from the flow rate (number of drops/min by volume/drop) and 
the volume of the catheter.
3.3 The accuracy of the estimation of the partition coefficient. 
The partition coefficient (A) is the ratio of the solubil­
ity of the diffusible tracer in the brain tissue to that in the 
blood.
i
3.4 Errors associated with measurements of optical density 
consistency.
3.5 Errors associated with the accuracy of the radioactivity 
counts of the tracer.
Description of the theoretical model and 
generation of data.
A computer (Cromenco System 3, with disc-driven micro­
processor units) was used for deriving the CBF data and assoc­
iated variable parameters.
The determination of local CBF, using the quantitative
14autoradiographic technique (Sakurada et al. 1978) with C- 
iodoantipyrine as tracer, is described in Chapter 2, Section 2. 
During the infusion of the tracer, 15-18 timed samples of arter­
ial blood were collected in pre-weighed filter discs. By the 
end of the infusion period the animals were killed by decapit­
ation, and the brains were quickly dissected and processed for 
quantitative autoradiography.
A typical arterial curve describing the concentration of 
the isotope and the time of the corresponding arterial sample 
is represented by Curve A (Figure 4). This curve was obtained 
by a "ramp” schedule of infusion, i.e., the rate of infusion 
was increased progressively. The other two extreme possibil­
ities are shown in Curves B or C (Figure 4). In Curve C the 
infusion of the tracer was started at a very high concentration 
and kept approximately constant until the end of the infusion, 
whereas in Curve B the infusion was given in a very low concen­
tration for a longer period and increased before the end of the
infusion. These curves are plotted in Figure 4 with their 
14respective C-iodoantipyrine concentrations, together with the 
time of collection of each blood sample for 30 or 60 second 
periods of infusion. The number of drops, kill-time, catheter 
lag-time, the partition coefficient, the time for the infusion 
of the tracer and optical density standards are shown in Table 13.
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Figure 4.
The local CBF input data  (Curve A,B and C)
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These data are inserted into the computer to have the best fit 
for the standards of optical density (see Table 14), and the 
CBF values are obtained for each curve. For the sake of 
simplicity these curves, with their respective data, are 
called Models A, B or C.
The original data were stored in the computer, and a 
programme for the effect of changing one of the three para­
meters, i.e., kill-time, lag-time, and the partition coeffic­
ient ( X )  on the estimated CBF value was designated by Dr. W. 
Angerson. For example, the cerebral blood flow (CBF) new 
values (2) in Model A at 30 sec infusion were as follows:-
Flow
Lag (min) Kill-time (min) Lambda (ml lOOg ~Snin )
1 2  1 2  1 2  1 2  
0.01 0.01 0.48 0.46 0.8 0.8 50 54
100 109
150 165
200 277
300 335
350 393
400 452
By this method the new blood flow values (2) are calculated when 
the new kill-time (0.46) is inserted.
The new values of the blood flow for Models A, B or C 
when the tracer is infused over 30 or 60 second periods are 
determined for the kill-time, catheter lag-time and partition 
coefficient (see Appendix I, Tables 1-17).
3.1 Errors associated with the accuracy of estimation of 
the kill-time.
Results
In Model A (30 sec infusion), an error of underestimation
of the kill-time within a value of one second will increase the
blood flow by 8-13%. Compared with a CBF base line ranging 
between 50 and 400 ml lOOg ‘''min \  a two-second underestimation 
of the kill-time will produce elevation in the blood flow by 
20-30%. By contrast, an overestimation of the kill-time by 
one or two seconds will produce reductions in the blood flow 
of 8-11% and 14-20%, respectively (see Figure 5, Appendix 1, 
Table 1). With a longer infusion time (60 sec), an under­
estimation by one or two seconds produced increases in blood 
flow of 4-9% and 10-20%, respectively. On the other hand, 
overestimation in the kill-time will produce reductions in flow 
levels of 4-9% and 8-16%, respectively (Figure 5).
In Model B (30 sec infusion), the blood flow levels
increased by 34-71% and 72-161% with an underestimation of the 
kill-time by one and two seconds, respectively, and overestimat­
ion by one or two seconds will reduce the blood flow by 28-37% 
and 48-58%, respectively. With 60 sec infusion, an error of 
one or two seconds of underestimation of kill-time increased 
blood flow values by 20-43% and 40-100%, respectively. With 
overestimation by one or two seconds, the CBF levels reduced 
by 16-27% and 30-44%, respectively (see Figure 6).
In Model C (30 sec infusion), the flow levels increased 
by 4-5% and 10-16% with an underestimation in the kill-time by 
one or two seconds, respectively. Overestimation in the kill- 
time in the same magnitudes produced reductions in CBF values of
8-10% and 4-5%. In Model C (60 sec infusion), an underestim­
ation or overestimation in the kill-time within a value of + 1 
or + 2 seconds will produce a CBF level ranging between + 2% to 
+ 10% (Figure 7).
3.2 Errors associated with the accuracy of the catheter
lag-time estimation.
The catheter lag-time is dependent on the catheter flow 
in blood flow experiments. The lag-time is corrected to the 
rate of the catheter flow in many laboratories, and catheter 
flow (ml min has been measured in our laboratory. It was 
found that the lag-time relationship to the catheter flow rate 
is as follows:
Catheter flow Catheter lag-time
(ml min""l) (min)
Greater than 2 0.02
1-2 0.03
0.8-1 0.04
0.6-0.8 0.05
Results
The lag-time correction and relationship to CBF are shown 
in Figure 8. In Model A (30 sec infusion), a lag-time correct­
ion by 0.02, 0.03 and 0.04 compared to a base line lag-time of 
0.01 reduced the blood flow by 4-6%, 8-10% and 10-15%, respect­
ively. In Model A (60 sec infusion), the blood flow values 
decreased by 2-5%, 4-9% and 6-12%, respectively.
In Model B (30 sec infusion), a lag-time correction with 
the same magnitudes reduced the blood flow by 14-22%, 28-37% 
and 38-49%, respectively. With a longer period of infusion
(60 sec), the blood flow levels decreased by 8-15%, 16-27% and 
22-36%. In Model C (30 or 60 sec infusion), the blood flow 
values reduced by 1-5%.
3.3 Errors associated with the accuracy of the estimation
of the partition coefficient.
Knowledge of the partition coefficient ( A )  is required 
for the quantitative measurement of CBF in all diffusible tracer 
techniques. This necessitates a special experimentation in 
which an equilibrium state must be attained for tracer concen­
trations in the blood and cerebral tissues, and then maintained 
over a sufficiently long period. The value of A  was reported 
by Sakurada et al. (1978) to be 0.8 in albino rats in which the 
tracer in the arterial blood was maintained at a constant con­
centration for at least two hours for blood:brain equilibrium.
In normal conditions, amounts of diffusible tracer which 
are contained in the arterial blood are redistributed between 
the brain and the blood according to respective solubilities.
In case of a diffusible tracer, A  is thus the ratio of the 
solubility of the diffusible tracer in the brain tissue to that 
in the blood (Kety, 1951).
Results
The relationship between errors in the partition coeffic­
ient and CBF is shown in Figures 9-11.
In Model A (30 sec infusion), when the partition coeffic­
ient ( A )  was reduced to 0.7 and 0.6, the blood flow values were 
increased by 2-22% and 4-60%, respectively. On the other hand, 
an elevation in the estimation of lambda by 0.09 and 1.0 decreases 
the flow levels by 2-11% and 2-18%. With a 60 sec infusion in
Model A, with lambda 0.7, the blood flow levels increased by 
4-67% compared to CBF base line range between 50 and 400 ml 
lOOg ^min When lambda was reduced to 0.6, the blood flow
levels increased by 8-89% compared with the CBF base line of 
50-200 ml lOOg ^min When there was an elevation in the
lambda to 0.9 and 1.0, the blood flow values decreased by 2-24% 
and 4-35%, respectively.
In Model B (30 or 60 sec infusion), the blood flow was 
increased by 0-7%, 2-17% and 2-10%, 4-25%, respectively, when 
underestimations of the partition coefficients were used at 
(0.8) by 0.7 and 0.6, respectively. In cases of overestimat­
ion of lambda to 0.9 and 1.0, the flows in Model B (30 or 60 
sec infusion) diminished to 0-5%, 2-9% and 2-8%, 2-13%, respect­
ively.
In Model C (30 sec infusion), flow levels varied between
50 and 350 ml lOOg "Snin \  and were increased by 2-56% when
lambda decreased by 0.01. With further decrease in lambda to
0.6, flow range between 50 and 250 ml lOOg ^min ^ increased by
6-120%. However, the flow levels decreased by 2-20% and 2-29%
when lambda increased by 0.01 and 0.02, respectively. In Model
C (60 sec infusion), a base line flow ranging between 100 and 
- 1 - 1150 ml lOOg min will increase by 14-35% when lambda is
-1 -1reduced to 0.7. Base line flow of 100 ml lOOg min increased 
by 49% with value of lambda of 0.6. In the case of lambda 
increases 0.9 and 1.0, the flow reduced by 8-45% and 13-54%,
respectively, compared with base line flow levels of 50-500 ml
-1 • -1lOOg min
3.4 Errors associated with measurements of optical
density consistency.
The data output of the densitometer is the "total inte­
grated density" of a feature or area of interest. This is the 
sum of the optical density contribution of each individual point 
within the detected region. For each brain region, 6 or 12 
bilateral optical density readings can be measured by the quant­
itative densitometric analyser (see Chapter II, Section 2.3).
The mean value and + SEM of these readings are obtained. The 
SEM for each brain structure is usually accepted in our laborat­
ory when it is + 10% of the mean optical density, approximately.
Results
The influence of a SEM of + 10% for optical density is 
shown in Figure 12 (see also Appendix II, Tables 18-23).
In Model A (30 sec infusion), a SEM of 0D of + 10% pro­
duced increases in the levels of blood flow by 12-25%, whereas 
a SEM of -10% reduced blood flow values by 12-20%. In Model A 
(60 sec infusion), + 10% produced increases in the flow by 12-21% 
in the CBF range 50-150 ml lOOg ^min \  and by 26-63% in the range 
200-400 ml lOOg ^min On the other hand, -10% decreased flow
values by 12-17% with CBF in the range 50-150 ml lOOg ^min \  and 
by 20-30% in the flow range 200-400 ml lOOg ^min
In Model B (30 sec infusion), a SEM of + 10% of the meas­
ured optical density increased the blood flow by 8-15%, and 
decreased by 12-14% compared with CBF range 50-400 ml lOOg ^min 
In Model B (60 sec infusion), + 10% produced elevations by 8-15%, 
and decreased by 12-14% in flow range 50-400 ml lOOg ^min \
In Model C (30 sec infusion), + 10% produced increases by
12-16% in the CBF values and -10% decreased the flow by 10-26% 
compared with the CBF levels of 50-400 ml 100g”'*'min’"^. In 
Model C (60 sec infusion), + 10% produced an increase in the 
flow by 20-67% in CBF range 50-200 ml 100g’"‘Snin""^.
3.5 Errors associated with the accuracy of the radio­
activity counts of the tracer.
Results
14
The C-iodoantipyrine blood sample concentrations assoc­
iated with errors produced by the liquid scintillation analyser 
within a value of -1%, -5% or -10% are shown in Figure 13a, b 
(see also Appendix III, Tables 25-30).
In Model A (30 sec infusion), an error of underestimation
14of radioactivity concentration of the C-iodoantipyrine within 
a value of -1% increased the CBF by 2-4% in flow levels range 
50-400 ml lOOg ^min \  whereas underestimation of -5% in the 
radioactivity produced an increase in flow by 8-14% compared 
with CBF range 50-400 ml lOOg ^min \  When the liquid scintill­
ation analyser failed to detect the radioactivity level by -10%, 
the blood flow elevated by 14-31%. In Model A (60 sec infusion), 
-1%, -5% and -10% in the radioactivity of the isotope increased 
the level of CBF by 2-5%, 6-27% and 14-77%, respectively.
In Model B (30 or 60 sec infusion), the tendency of 
increasing the level of CBF with underestimation of the tracer 
counts is generally the same in both 30 and 60 second periods 
of infusion. ' ■
In Model C (30 sec infusion), underestimation of -1%, -5% 
or -10% increased the CBF by 2-4%, 8-24% and 14-78% compared to 
CBF range 50-400 ml lOOg ^min \  Underestimation of the isotope
concentration in Model C (60 sec infusion) by -1% increased the 
flow levels by 2-20% compared to CBF range 50-400 ml lOOg ^min  ^
and a decrease in the tracer counts by -5% produced an increase 
in CBF levels by 12-121% compared to CBF range 50-300 ml lOOg  ^
min \  Further reduction in the isotope concentration by -10% 
increased the CBF levels by 20-85% compared to CBF range 50-200 
ml lOOg ^min \
Summary of the potential errors associated with
measurements of local CBF.
Errors of the kill-time.
It is important to have the accurate kill-time for the 
blood flow experiments. Errors in estimating that are more 
likely to add a variable factor. The sacrificing of large 
animals (baboons) is technically more difficult than small 
animals (rats). Investigators may use Kcl to arrest the 
circulation. The possibility of having errors of either 
over- or underestimation of the accurate kill-time is greater 
in these circumstances. It is more accurate to have a blood 
data curve situated between Models A and C to minimise the 
influence of inaccuracy of kill-time estimation of blood flow 
data.
Errors of the lag-time.
Models A and C tolerate errors associated with lag-time 
correction better than Model B. There were no significant
i
differences in the errors in models conducted over 30 or 60 
sec infusions.
Errors associated with the partition coefficient.
It is necessary to show concern in quantitative meas­
urements of blood flow in pathological conditions (cerebral 
ischaemia, cerebral neoplasm, cerebral oedema, etc.), where 
may be changed. The measurements of blood flow in the present 
studies (see experimental design) were made 30 min after middle 
cerebral artery occlusion. Eklof et al. (1974) suggested that 
there were no major changes in the partition coefficient, partic­
ularly in ischaemic areas with low blood flow. Thus, these 
changes in X  make relatively minor differences to the calculated 
levels of CBF.
Errors of the optical density measurement.
It is also important to avoid the problem of thick and 
thin sections of the brain when measuring the optical density 
of the CNS regions. The calibration and stability of the 
Quantimet densitometer is also important, to avoid variation 
in optical densities.
14
Errors of the C-IAP estimation.
14
Inaccurate estimation of the C-iodoantipyrine concen­
tration by liquid scintillation analysis is an important factor 
associated with the variability of CBF data. Underestimation 
of the isotope's radioactivity concentration produces increases 
in CBF values in all types of blood flow experiments. It is 
obvious from the results that a 30 second period of infusion 
tolerates errors produced by the liquid scintillation analysis 
better than that of 60 seconds (see Figure 13a and b).
The bleaching of blood samples containing the tracer (see 
Chapter II, Section 2.2) is an important procedure to reduce the
possibility of colour quenching. The -vials of the blood 
samples should be allowed to remain at room temperature for 
at least two hours for bleaching to proceed. it is equally 
important to check the calibration of the liquid scintillation 
analyser, together with monitoring the accuracy of the measure­
ment, by using two vials (usually 7 and 10) from each blood 
flow experiment subjected to the internal standard method.
In the experimental work in this thesis, the use of 
"ramp" schedule infusion over 30 sec resulting in having blood 
flow data resembling Curve A. The maximum errors related to 
under- or overestimation of the kill-time in Model A (30 sec 
infusion) were elevation in the CBF by 13% (underestimation of 
the kill-time by 1 sec), and reductions in the blood flow levels 
by 11% (overestimation of the kill-time by 1 sec) compared with 
a CBF base line of 400 ml lOOg ^min
As shown in the results, Model A (30 sec infusion) mini­
mised the influence of inaccurate estimation of the kill-time 
on the CBF levels. Furthermore, the use of small animals (rats) 
made it technically possible to have accurate estimation of the 
kill-time.
In Model A (30 sec infusion), a lag-time correction by 
0.02 compared to a base line lag-time of 0.01 reduced the blood 
flow by 4-6%. In the majority of the blood flow experiments 
conducted in the present studies, the catheter flow was greater 
than 2 ml min "S therefore, the catheter lag-time was 0.02 (min).
During the measurements of the optical density of the
/
brain regions, the problem of the thick and thin sections was 
avoided and careful calibration of the Quantimet was performed.
The use of Model A (30 sec infusion) in this thesis takes into 
account both biological variability and experimental errors.
M
od
el
 A 
=3
0s
ec
on
ds
 
M
od
el
 A
=6
0 
se
co
nd
s
71
o
r-O
o
ft? ~  
e
o
0
o 1“
1
LL
ca
o
o-o
oho
oho
C9 *'“*
'09oo
O ▼“ho __w g
U.
CD
O
T
O
Toco
T
O
CNJ
I
0 
CM
1
0’a-1
o
E
•H
-P11
rH
rH
•H
tw
O
CO
•H
•P
0$
E
•H
-P
m
o
h
a
>
°
°
c
o
•H
•p
05
E
•H
-p
CO
d)
u<u
T3
C
3
0
-P
T3
d)
-P
cd
rH
(D
U
rHl1C
•H
E
rH■
to
o •
o o
rH <u
(0
rH
E OJ
+ 1
fo
CQ <HO
d)
o 3
rH
>> 05
■p >
•H
rH aJ
•H
XI C
05 *H
*H JZ
u -P
05 •H
>
in
( lo j ju o o  iu o j j  a B u e q o  % ) j g o
o
u
3
to•H
pt<
I
r'
CB
F(
%
 
ch
ar
ge
 
fro
m 
co
nt
ro
l)
Figure 6.
120
100'
9 0'
8 0 '
Model B=60secondsModel B=30seconds
6 0 '
50-
40-
3 0 -
20-
10'
1sec
-2sec
10-
- 20-
- 3 0 -
- 4 0
- 5 0 -
- 6 0 -
100 300 100200
CBF(ml lOOg’min1)
4 0 0 200
CBF(ml 100g1min1)
300
Variability of CBF (ml lOOg ^min related to underestimation
or overestimation of kill-time within a value of + 2 sec.
M
od
el
 C 
=3
0s
ec
on
ds
 
M
od
el
C
=6
0s
ec
on
ds
u O V
0 0 0
(0 tn M
CM r- CM
1 + +
•••9
f999
'c
E
Oo
n.
DQ
O
'c
I
oo
ll
CQo
<D
E :
•H
■p
i
rH
rH
•H
X
<H
o
co
•H
-p
0
E
•H
-p10
0
u
0
>O
o
c
o•H > 
-p' 
td * 
E 
•H 
■p (0 fl)
u
0
•o
c
3
O
-P
T3 
0 
-P 
0 i—I 
0 
u
I—I
IGOOO o
rH 0w
rH
CM
+1
m <Ho o
<H 0o 3
rH
>» 0•p >
•H
i-H 0
iH
£3 C
0
•H s:p -p0 •H> 5
•
0
u
3; no
•H
! ^
( I o j j u o o  l u o j j  e 6 u e n o o /0)  j g Q
CO■Oc
o
o0)
CO
Q
CO
I
<
o5
■a
o
CO■oc
oo
CD
COo
CO
<:
aj■o
o
2
CM COo o
o
ICDa
o
it 1a
ca
o
o
na>«a
co
■oc
o
o
<D
COO
COl
CQ
~Q)
*o
O
2
■O
■4
i i ‘t co■Oc
oo
CD
COo
COIo
aj■a
o
*
o
r-O
•Or- 
CO ic
1C)
o
o
SiN E
s-r
U_
m
o
o
h-O
o-o
O^ fs
“§ 1E
ET~
IO)oo
° C- o £CM u_
C0 
O
( | o j j u o o  w o j j  e S u B i p  % )  j g o
*
1—1
o•
°
1 +
j «H
1 0
i ^
! 3
i 1—^S <0
; >
i d
i c
I *H
1 ■P
S  >
co
•H
■po
(D
U
! h
°
! °
i 05' e •
•H
; P rH
I 1 o
DO •to o
rH —
o a)
-p E
•H
03 ■p
<D i
-P to
CO (0
i r“* 1—1<D
U rH
O
«•— U
rH -P
1 c
c o
•H O
E
rH O
1 -P
COo TOo <DI—1 U
(0
1—1 a■ E E
Oo
CQ ■»
O COoCh •
O o
>> +
-P
•H u
rH o
•H
CM
(0 O
•H •
U o(0
> +
CO
! a)
i h
! 3to
i
i
M
od
el
 
A
=3
0s
ec
on
ds
T3
I— 7 <L cL o i i c L i
W  CM »- r- C\J C9
I I I
(Io j j u o o  u j o j j  a 6 u e q o  % ) j q o
o
r-O
§T=
o g
7o>oo
°  E■O *3 
CM ^
CD
O
oho
o
CO|C
10)Oo  
ho E
" cm
o
o
ho
co
+5
•H
-p
0
a
o
x
-p •
<H CD
o •
O
co <H
•H o
-p
0 0
E
•H rH
•P 0
CO >
0
hi rH
0 O
> hi
o -P
c
h. o
o o
c 0o
•H x:
-p ■p
0 •H
E ?
*H
-P 73
0 0
0 U
u 0
0 Q.
73 E
c O
3 a
o
•p CM
o
73 #
0 O
-P
+  1
«H
0 h.
o
rH
rH • #
i o
c
•H + 1
E
«—1 <H
1 obO
O 0
o 3
rH rH
0i—1 >
E 0
c
CQ •HO x:
-p
<H •H
1 o >
>i -P-p G
•H 0
rH *H
•H O
.a •H
0 <H
I *H <H
! k 0! cd o
i > o
O)
0
u
G
bO•H
M
od
el
 
B=
30
 
se
co
nd
s 
M
od
el
 
B=
60
 
se
co
nd
s
*
<r
CO
I — T
CM
I
O t
tO 0}
o o
n-< i-<
!  f  1i
i f
,  i  , ■
o
CM
T
co
i
o-o
h°ic
” 1
To
h Oo
-S e
" u .:
CDo
o
ho
oho
1C CO —
E
To 
>- o  o
CM Li.
m
o
o-o
0
M-
1
co
•H
■p
•H
-p
u
cO
a
a>
x:
•p
«H
o •
00
c •
o o•H
■p Ch
as o
E•H ©
-p 3
w iH
V to
p >
V
> iH
o o
u
u -p
o c
o
c o
o
•H (0
•p
(0 x:
E ■p
♦H
•p ■?
w
QJ TO
U ©V u
TJ (0
C a
P EO
o o
-p
•a CM
a) O
-p •
o
r—1 ,
©
o
H
rH •
1 o
c
•H + 1
E
rH <H
1 obO
O ©
o piH iH
CO
rH >
E
(0
fcr c
! CQ •H
! o x:
| -p
«H •H
1 0
1 >> -p
1 -P ci *H <u
pH •H
•H O
Xi *H
: as Chi *H ch
i h 0)as O
: > O
(lojjuoo ujojj eBueiio%)jaD
or—I
0)
Jh
PCtO•H
M
od
el
 C
=3
0s
ec
on
ds
 
/ 
I 
M
od
el
 
C
=6
0s
ec
on
ds
N.
O
I
-<
i o i 6 i A i
co m  tj- co cj t - CM COI I
(lojjuoo u i o j j  eSueqo % ) J 8 0
; coI •H
j -p
•H
: •p
ch
I cO
o P.
o
Si.
•P
m | Ch
o •
i CO/—s c •
-STs 1 o♦H o
co 'E  i. r*
-p Ch
co o
ID) E
d)O •H
" o ■pW
P
i—iT“ <D (0._ Ch >
°  E  ; <D
" °  w > rH«M U . o o
CO Ch
u  I Uo
-P
eo
C o
O  '
o
•H (0
-o •PCfl s:
E -p
i •H •H
| -P
to
i d) TJ
Ch a)
<D Ch
X} (0
- ° C a
P Ei o
o o
°  i ■P-o  ! •*
TJ OJ
Q) o
1 +> •i CO o• i rH
d> Ch
U O*"N
O ’-
- o i c r— rH
” 1
rH
1 o
c
+  1IO) •H
-  o E
Cho i-H
1 o
W)
o o d>-o C o P
w i r rH i—l(0CD rH >O 3 (0“
! Eh c
i ® •HO oi s:- o •p•r* •H
1 o %
I >> -P• +> cj ♦H d>
1 1-1 •H! -H O
I £> •H-O i CO Ch
ch
i u d>
j CO O
I > O
Fi
gu
re
 
11
.
( lo jju o o  w o j j  e B u e ip  % ) j q q
Fi
gu
re
 
12
. 
Va
ri
ab
il
it
y 
of
 
CB
F 
le
ve
ls
 
an
d 
re
la
ti
on
sh
ip
 
to 
op
ti
ca
l 
de
ns
it
y 
me
a
s
u
r
e
m
e
n
t
 
wi
th
in
 
a 
va
lu
e 
of
 
+ 
10
%.
■o
co
■o
c
o
o
0
CO
o
COI
m
0
"O
o
2
\
CO
TJ
co
o0)
CO
o
CO
o
*o
o
2
\
i r 
o o
CO CM
o
r O
£ ,c CO —
E
Tc?
o
°  Eo *5
CM ll
CQ
O
-o
S'.E
E
r-o>IO
o
°  Eo
CM LL
CQ
O
c
•H
x.
•H
co
•rH
-p
0
E
•H
4->
CO
0
G
0
Tf
C
3
0
G
•H
g
>>
a
•H
-P
G
0o
0  
•H
1
T3
C0
( lo j ju o o  ujojj e B u e ijo  % ) j g Q
c
•H
E
•HI
GO •O 55o o
rH rHI
; rH
1
‘ E T3
C
0
U*
CQ 55
O in■
<H
1
O «*
t>> rH
4-3 i
•r4
rH «H
•H O
JO
0 0
•H 3G rH
0 0
> >
•
0
CO
•H
0
G
3
GO
•H
\
M
od
el
 
C
s3
0s
ec
on
ds
 
, 
M
od
el
 
C
=6
0s
ec
on
ds
° ' E  
" E
IO)oo
g j
cm LL 
CD 
O
CO 1C
ionoo
° E o S
CM U_
m
o
c
•H
s:p*H
co*H
p
d
E
p
(0
0
Li0•ac
P
0
c•H
u>)a
•H
P
O•a
0
•H1
o
(lojjuoo u i o j j  ©Bueqo %)jaO
TD
§
IG
•H
E
iHi
DOOo
rH
CQO
<H
o
>»
p
•HH
•H
•§
•HGd
>
Si
CO
0
g
3,
•H
fin
O
73C
d
in
l
I—I
I
<H
o
0
piH
d
>
I
4. Measurement of Local Cerebral Glucose Utilisation
Local cerebral glucose utilisation was measured using
14
the C-2-deoxyglucose technique (Sokoloff et al. 1977).
4.1 Theory.
The knowledge about the brain energy metabolism has been 
obtained from the estimation of cerebral metabolic rate of oxy­
gen, using the nitrous oxide technique (Kety and Schmidt, 1948) 
and its modifications (Scheinberg and Stead, 1949; Lassen and 
Munck, 1955; Eklof et al. 1973; Gjedde et al. 1975) which 
measures the average rates of energy metabolism in the whole 
brain.
Oxygen and glucose use are the normal substrates of
cerebral energy metabolism. Under normal circumstances, the
brain uses glucose primarily to fuel many biochemical reactions
necessary for cerebral function (Gibbs et al. 1942; Kety, 1948;
Hawkins et al. 1974; Sokoloff et al. 1977; Siesjo, 1978).
Measurements of the oxygen uptake or glucose use by the
brain provide an index of neuronal functional activity of the
brain (Kennedy et al. 1975; Sokoloff et al. 1977). Sokoloff
et al. (1977) have established a method which measures the rates
of energy metabolism in specific discrete regions of the brain
in normal and altered conditions of the functional activity by 
14
employing the C-2-deoxyglucose autoradiographic technique.
14
Thus, the limitations of the C-glucose method (Hawkins et al. 
1974) can be avoided.
The only difference between 2-deoxyglucose and glucose 
is in the hydrogen atom attached to the second carbon in place 
of a hydroxyl group. Sokoloff's technique (1977) for the
measurement of cerebral glucose utilisation was based on taking 
advantage of the absence of this hydroxyl group from the molec­
ular structures of 2-deoxyglucose. Both sugars have been 
shown to share the hexose transport system; transport system 
between the blood and brain (Oldendorf, 1971; Horton et al. 
1973). In cerebral tissue, both sugars are substances for 
the hexokinas'e reaction, in which they are phosphorylated to
2-deoxyglucose-6-phosphate and glucose-6-phosphate (Sols and 
Crane, 1954). 2-Deoxyglucose-6-phosphate, unlike glucose-6- 
phosphate, is not a substrate for glucose isomerase or glucose- 
6-phosphate dehydrogenase, and its catabolism ceases at this 
point (Sols and.Crane, 1954; Wick et al. 1957; Tower, 1958; 
Horton et al. 1973). Deoxyglucose-6-phosphate can be broken 
down to deoxyglucose by glucose-6-phosphatase (the action which 
results in the hydrolysis of deoxyglucose-6-phosphate to deoxy­
glucose). In cerebral tissue, the activity of this enzyme is 
very low (Raggi et al. 1960; Prasannan and Subrahmanyam, 1968).
The mathematical model for the quantitative determinat­
ion of regional glucose utilisation (Figure 14) was developed
14
on the assumption that the C-deoxyglucose phosphate is 
essentially trapped in the cerebral tissue, and it is neither 
metabolised further at an appreciable rate nor lost from the 
site of phosphorylation (Sokoloff et al. 1977). Some invest­
igators (Hawkins and Miller, 1978; Hawkins, 1980; Sacks et 
al. 1983) questioned the basic premise of the procedure, and 
doubted if the loss of deoxyglucose phosphate could be ignored. 
However, no convincing evidence against the method emerged from 
these investigations. Subsequently, a number of detailed 
reviews have been published in which the features of this
particular method were emphasised (Sokoloff, 1978, 1979,
1981a,b,c, 1982; Sokoloff et al. 1983).
14The main limitations and conditions of the C-2-deoxy- 
glucose technique are:-
a) The value of the lumped constant and the kinetic
constants must be known for the region and species 
being investigated.
b) The cerebral glucose utilisation and the plasma
glucose concentrations remain constant throughout
the period of measurement.
14
c) The C-deoxyglucose and glucose concentrations in
the arterial plasma are representative of those in 
cerebral capillaries.
The operational equation which allows the rate of glucose 
utilisation to be described mathematically is illustrated in 
Figure 15. Although the operational equation seems to be com­
plex, it should be recognised that it is simply a specific form of 
a generally used equation by which the rates of the biochemical 
reaction with the tracer can be measured. The operational 
equation (Figure 15) can be written in a simple way as:-
14Rate of glucose _ Total tissue C - tissue 2-DG 
utilisation - Lumped constant x integrated 
plasma specific activity.
14Total C in cerebral tissue is obtained via the densit­
ometer; the tissue 2-deoxyglucose and integrated plasma activity 
are calculated from plasma histories of 2-deoxyglucose and glucose. 
The values for the rate constants and lumped constants for the 
operational equation were:-
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Legend to Figure 14.
Diagrammatic representation of the theoretical model. 
represents the total concentration in a single homogen- 
eous tissue of the brain. Cp and Cp represent the concen­
trations of ! > c ]  deoxyglucose and glucose in the arterial
*
plasma, respectively; Cg and Cg represent their respective
concentrations in the tissue pools that serve as substrates
for hexokinase. represents the concentration of
deoxyglucose 6-phosphate in the tissue. The constants 
* * *
k^, k£, and kg represent the rate constants for carrier- 
mediated transport of [14cJdeoxyglucose from plasma to 
tissue, for carrier-mediated transport back from tissue to 
plasma, and for phosphorylation by hexokinase, respectively. 
The constants ki, k2 and kg are the equivalent constants for 
glucose. D^cJDeoxyglucose and glucose share and compete
for the carrier that transports both between plasma and 
tissue for hexokinase which phosphorylates them to their 
respective hexose 6-phosphates. The dashed arrow represents 
the possibility of glucose 6-phosphate hydrolysis by glucose 
6-phosphatase activity, if any. (From Sokoloff et al 1977).
Figure 15.
General Equation for Measurement of Reaction Rates with Tracers
Rate - of Reaction -
Labeled Product Formed in Interval of Time, 0  to T
Isotope Effect 
Correction Factor
Integrated Specific Activity 
of Precursor
Operational Equation of [ l4C]Deoxyglucose M ethod:
Labeled Product Formed in Interval of Time, 0  to T
Total ,4C in Tissue '“"C in Precursor Remaining in Tissue at Time, T 
at Time, T ■---------------------------------- "------------------------------- ‘
C;(T) -  k
R; =
+ e -(k* + kl)jf C p e ^k2+k3
Jo
)t dt
0 ‘Vm'Km
A l p ) dt _
Jo p  Jo  p
)t dt
Isotope Effect Integrated Pasma Correction for Lag in Tissue 
Correction Specific Activity Equilibration with Plasma
Factor     ,
Integrated Precursor Specific Activity m Tissue
Operational equation of radioactive deoxyglucose method and its 
functional anatomy. T represents the time at the termination of 
the experimental periodj Ac equals the ration of the distribution 
space of deoxyglucose in the tissue to that of glucose; 0 equals 
the fraction of glucose which, once phosphorylated, continues 
down the glycolytic pathway; and K^, V *  and Km , V m represent the 
familiar Michaelis-Menten kinetic constants of hexokinase for 
deoxyglucose and glucose, respectively. The other symbols are
the same as those defined in Figure 14. (From Sokoloff, 1978).
Gray Matter White Matter
V 0.189 (min ^) 0.079 (min ^)
K2* 0.245 (min ■*■) 0.133 (min ^)
V 0.052 (min )^ 0.02 (min )^
"Lumped Constant" - 0.483 for the albino rat, 
(Sokoloff et al. 1977).
4.2 Practice.
Measurement of local cerebral glucose utilisation was
performed on conscious rats, prepared as described previously, 
14
employing the • C-2-deoxyglucose technique (Sokoloff et al. 
1977). For each experiment the isotope (50 pCi per animal), 
dissolved in saline, was given at a constant rate over 30 
seconds. A total of 14 timed samples of arterial blood were 
withdrawn from the femoral cannulae and collected into heparin- 
ised plastic centrifuge tubes over the subsequent 45 minutes 
according to a pre-determined time schedule. The volume of 
the arterial samples was approximately 75 pi of whole blood, 
and this same volume was replaced by saline solution. The 
arterial blood plasma was separated by centrifugation within 
a few minutes of withdrawal. Of each plasma sample, 20 pi 
was pipetted from the centrifuge tubes into 1 ml of distilled 
water in 14 plastic scintillation vials. The glucose level 
was determined, using a 10 ul aliquot of plasma and a semi­
automated glucose analyser (Beckman) with a glucose oxidase 
method. At the end of 45 minutes, the rat was killed by 
decapitation and the brain processed for quantitative auto­
radiography in the same manner as for the measurement of local
cerebral blood flow. The potential errors associated with the
I"l4 1measurement and modification of the CJ-2-deoxyglucose tech­
nique have been discussed in detail elsewhere (Kelly and 
McCulloch, 1983b). Therefore, these errors were not studied 
in this thesis.
5. Neuropathological Studies
5.1 Perfusion fixation.
Perfusion fixation was performed in those animals used 
for histopathological assessment 3-4 hours after MCA occlusion. 
Approximately 3-5 min prior to sacrifice, anaesthesia was 
deepened by increasing the halothane concentration to 2%.
A thoracotomy was made and the pericardium opened. The apex 
of the left ventricle was incised and a cannula was introduced 
into the ascending aorta. The tip of the right atrium was cut 
and body perfusion was performed with 40 ml of heparinised saline 
(1.5 ml heparin in 40 ml physiological saline). Fixation was 
then carried out with FAM (40% formaldehyde, glacial acetic acid 
and absolute methanol, 1:1:8 by volume). The FAM solution was 
infused slowly so that the arterial blood pressure was maintained 
within the range of the pre-sacrifice perfusion pressure and the 
rate adjusted by reference to the MABP trace. After infusion 
of 150-180 ml of FAM, the rat was decapitated and the head was 
stored in FAM for at least 12 hours. The brain was then removed 
and embedded in 10% formal saline for a minimum period of 24 hours 
at 40°C to ensure complete fixation.
5.2 Sectioning and staining for quantitative analysis.
The sectioning and quantification of ischaemic damage 
was performed according to the method of Graham et al. (1984). 
The animal was perfusion fixed with FAM. After removing the 
brain, the cerebral hemisphere was cut into four coronal slices 
of approximately equal thickness. These coronal slices were 
embedded in a paraffin wax block. Sections of 10 u thickness 
were taken at 250 u intervals through the block for histopatho- 
logical examination. These sections were stained by a method 
combining cresyl violet and luxol fast blue, and haematoxylin 
and eosin. This method would produce multiple levels, each 
containing four different coronal sections. By this method 
the forebrain was effectively represented by about 36-48 
equidistant coronal slices, thus enabling the extent of cell­
ular ischaemic damage produced by middle cerebral artery 
occlusion to be assessed more fully than previously (Tamura 
et al. 1981a).
The histopathological changes were examined by convent­
ional light microscopy. The brain sections showing ischaemic 
lesions were determined according to the histopathological 
criteria of Brown and Brierley (1968) in FAM perfusion-fixed 
animals. A good perfusion fixation was judged by the absence 
of intravascular blood, and the lack of cytological artefacts 
such as "dark cell" or "hydropic cells" (Cammermeyer, 1961; 
Brown and Brierley, 1968).
5.3 Determination of the area of ischaemic damage.
Areas of brain showing ischaemic cell damage were drawn 
directly on.to eight stereotactically determined coronal levels
of the brain from an atlas of rat neuroanatomy (Konig and 
Klippel, 1963). The selected coronal levels with their 
anatomical location and anterior co-ordinates (mm) were as
follows:- 
1. Intermediate olfactory tract 10.50
2. Nucleus accumbens 8.92
3. Septal nuclei 7.19
4. Globus pallidus 6.06
5. Anterior hypothalamus 5.15
6. Lateral habenula 3.57
7. Medial geniculate body 2.18
8. Cerebral aqueduct 1.02
The areas of ischaemic damage which were drawn on to
(Figure 16) were obtained by the image analyser function of
the densitometer (Quantimet 720, Cambridge Instruments). The
map was placed on an epidiascope stage and the image of the
coronal sections was projected on to the densitometer screen.
The area of the ischaemic cell damage was delineated by an
electron "light" pen. The size of the area depicted was
proportional to a picture point number displayed on the screen.
2
A magnification of 360 picture points per mm on the predeter­
mined map was used.
5.4 Measurement of the volume of ischaemic damage.
The total volume of the ischaemic damage was obtained by 
knowing:
a) the linear magnification of actual brain size (4X),
b) the magnification factor from map to densitometer
2
(360 picture points per mm ).
Figure 16.
G>
Diagrammatic representation of coronal sections of rat brain 
which have been used for quantitative assessment of neuro- 
pathological damage following MCA occlusion.
c) The picture points numbers displayed on the screen
which is proportional to the area of ischaemic 
cell damage.
The total volume was then calculated by plotting the areas of 
2
damage (mm ) against the eight coronal sections with reference 
to distance between the sections (mm). A computer (Cromenco 
System 3) was used for deriving volumes of the ischaemic damage.
6. Experimental Design
6.1 The effect of vehicle and saline on physiological 
variables in anaesthetised rats.
The effect on the physiological variables of continuous 
infusion of the nimodipine solvent (lutrol-glycerine-water 
solvent) was examined. Following completion of the surgical 
preparation (see ChapterII, Section 1.1) at least 30 minutes 
were allowed to elapse before the infusion of the vehicle was 
started (n=6). Normal saline was infused into another series 
of animals (n=6). The volume of infusion was 0.0136 (ml kg  ^
min ^) for 60 minutes. Arterial blood samples were taken 
immediately before infusion of vehicle or saline, and in these 
were measured the PCO^, PO^, pH and plasma glucose concentrat­
ion. thereafter the measurements were repeated at intervals
of 30 minutes.
6.2 The effect of nimodipine on local CBF in 
anaesthetised rats.
The effect of continuous infusion of nimodipine (1, 2 or 
4 jig kg ^min ^) on CBF was studied in anaesthetised, mechanic­
ally ventilated rats. Following completion of the surgical
preparation (see Section 1.1), at least 30 minutes were allowed 
to elapse before the start of infusion of the drug or vehicle.
This was done to achieve normoxia, normocapnia, stability of 
the blood pressure, and normal plasma glucose concentration. 
Normocapnia was achieved by adjusting the tidal volume of the 
respirator. In control experiments (7 animals), the lutrol- 
glycerine-water solvent alone was infused via the femoral vein 
one hour before measuring local CBF. In nimodipine treated 
animals the rates of drug administration were 1 jag kg "Snin ^
(6 animals), 2 pg kg ^min ^ (7 animals) and 4 jag kg ^min ^
(7 animals). CBF was measured 60 min after the start of
infusion of the drug; the volume of infusion was 0.0136 ml
. -1 . -1kg m m
6.3 The effect of nimodipine on local CBF and local CGU 
relationship in conscious rats.
The effect of a continuous infusion of nimodipine on local 
CBF and local CGU was studied in conscious rats. In control 
experiments, rats were infused with the lutrol-glycerine-water 
vehicle and comparisons were made between these and rats treated 
with nimodipine (5 animals for CBF and 7 animals for CGU). The 
dose of nimodipine in each of these experiments was 1 jag kg ^ 
min \  The measurement periods of the two techniques differ 
(30 seconds for blood flow, 45 minutes for 2-deoxyglucose experi­
ments), and the initiation of the experiments was therefore timed 
so that the median points of the measurements coincided. Thus, 
the experiments to determine local CBF were initiated 25 minutes 
after commencing the i.v. infusion of either nimodipine or vehicle, 
and those in which LCGU was measured were initiated 15 minutes
after commencing the infusion of either the nimodipine or the 
vehicle. Administration of the drug or solvent was continued 
until sacrifice of the animal. Although this experimental 
design aims to ensure that the measurements of blood flow and 
glucose use have as close a temporal similarity as possible, 
there are a number of attendant difficulties, in particular 
related to the drug infusion. For example, there is a differ­
ence of approximately 30% in the calculated arterial nimodipine 
concentration at the initiation of the CBF measurement compared 
to the value calculated at initiation of the measurement of 
glucose use (see Chapter I, Section 3.2.4). It should be 
recognised, however, that although the vasomotor effects of 
nimodipine in vitro are dose-related (Towart et al. 1982; 
Andersson et al. 1983), the relationship between the concen­
tration of nimodipine administered and the alteration in cere­
bral blood flow in the intact animal is more complex because 
of the associated systemic hypotension induced by the drug 
(Haws et al. 1983; Mohamed et al. 1984; McCalden et al. 1984).
These difficulties encountered in pharmacological investigations
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using the autoradiographic C-2-deoxyglucose and C-iodoanti-
pyrine techniques are an inevitable consequence of the different 
periods over which the measurements are made, and are well 
recognised. The timing of the isotope administration in the 
present experimental design does provide the most represent­
ative determination of CBF for comparison with glucose utilis­
ation, even although the latter is averaged over a longer period.
6.4 The effect of nimodipine on focal cerebral ischaemia.
6.4.1 The effect of pre-treatment with nimodipine
(1 jig kg ^min on local CBF in anaesthetised 
rats following MCA occlusion.
The effect of pre-treatment with, nimodipine (1 jig kg~^ 
min on local CBF in rats with MCA occlusion was examined.
In control animals (5 animals) and in nimodipine pre-treated 
animals (5 animals), the vehicle and nimodipine were both 
infused for 30 minutes before MCA occlusion, and the infusion 
was continued for 30 minutes after the MCA occlusion. The 
nimodipine plasma concentration 60 minutes after infusion was 
calculated to be approximately 58 nM (see Chapter I, Section 3). 
The local CBF was measured as desribed (Chapter II, Section 2). 
In addition, the frequency distribution analysis of the local 
CBF was determined as described in Chapter II, Section 2.3,2.
6.4.2 The effect of pre-treatment with nimodipine 
(2 jig kg ^min ^) on local CBF in anaesthet­
ised rats.
The effect on local CBF of pre-treatment with continuous 
intravenous nimodipine (2 jig kg ^min ^) was examined in rats 
with middle cerebral artery occlusion. In control untreated 
animals (9 animals) and in nimodipine treated animals (7 anim­
als) the infusion was commenced 30 minutes before MCA occlusion 
and continued for 30 minutes thereafter.
6.4.3 The effect of pre-treatment with nimodipine 
(1 jig kg ^min ^) on the neuropathological 
findings in anaesthetised rats following 
MCA occlusion.
The effect of pre-treatjnent with nimodipine (1 jig kg  ^
min ■*") on the histological findings in rats after MCA occlusion 
was investigated. In control (n=8) and nimodipine treated 
animals (n=8), the infusion of the drug or vehicle was started 
30 minutes before MCA occlusion and continued for at least 3-4 
hours, at which time perfusion fixation with FAM was performed. 
Measurements of brain sections and the volumes of brain showing 
ischaemic cell damage were made by a quantitative method (see 
Chapter II, Section 5).
The assessment of histopathological changes was conducted 
without prior knowledge of the schedule of treatment. Each 
experiment was given a code number. After obtaining the results 
of each experiment, the code for the whole series was broken and 
the statistical analysis of the results was performed thereafter.
6.4.4 Effect of post-treatment with nimodipine 
(1 jig kg ^min on local CBF in rats 
following MCA occlusion.
The measurement of local CBF was performed 35 minutes 
after occlusion of MCA. In five experimental animals, intra­
venous infusion of nimodipine (1 jig kg \iin was started 5 
minutes after MCA occlusion and was continued for 30 minutes 
until sacrifice. In the 5 control animals a similar volume 
of the solvent was used. Arterial blood samples were taken 
immediately before occlusion of the artery, and immediately 
before measurement of CBF for the determination of PaO^,
PaCO^, pH and plasma glucose concentration.
7. Statistical Analysis
Data are presented as mean + standard error of the mean 
(SEM). In the blood flow investigations, unpaired Student's 
t-test was used for comparison between the vehicle infused 
and nimodipine treated animals. For comparison between ipsi- 
lateral and contralateral side to the middle cerebral artery 
occlusion, paired Student's t-test was used. The multiple, 
non-independent measurements of the brain regions in each 
animal and various dosages of the drug administered in this 
study need more conservative statistical treatment. The 
Bonferroni correction factor, which has been suggested to 
reduce the error which may occur in using multiple t-testing 
(Wallenstein et al. 1980; Ford, 1983), has been used.
The analysis of the relationship between cerebral blood 
flow and glucose utilisation, the gradient (m) and coefficient 
of correlation (r) were derived from linear regression analysis 
to obtain the best fit of the data to the line (y=mx+b). 
Although this form of data analysis is not appropriate for. 
rigorous statistical analysis, it does provide an easily 
assimilated graphic display (see McCulloch et al. 1982). 
Therefore, the relationship between the natural logarithms of 
mean LCBF and LCGU in control animals and animals that receiv­
ed nimodipine was used.
In the neuropathological studies, the a priori hypothesis 
that nimodipine reduced the volume of ischaemic damage in the 
cerebral cortex was tested with one-tailed Student's t-test.
The possibility that the area of ischaemic damage at each 
stereotactic level was altered by nimodipine pretreatment was 
examined with the more conservative two-tailed Student's t-test.
CHAPTER III 
RESULTS
1. Effect of Vehicle and Saline Administration on 
Physiological Variables in Anaesthetised Rats
The majority of animals used as a control in this thesis 
were receiving vehicle (lutrol-glycerine-water solvent). Some 
animals used as a control in ischaemia received saline. In 
these animals the effect of pre-treatment of continuous intra­
venous infusion.of nimodipine (2 pg kg ^min see Chapter III, 
Section 3.2) on local CBF was investigated. Therefore, twelve 
animals (weighing between 370 and 480g) were used to find whether 
the administration of vehicle or saline produced any changes in 
the MABP, blood gas tensions, plasma glucose concentrations and 
arterial pH. There were no significant alterations in PCO^,
PO^, arterial plasma glucose concentrations and arterial pH in 
any groups (Table 15). The infusion of either lutrol-glycerine- 
water solvent or physiological saline did not significantly change 
the MABP (Table 16).
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2. The Effects of Nimodipine on the Cerebral Circulation 
in Normal Brain
2.1 Effect of nimodipine on local CBF in anaesthetised rats:
relationship to arterial blood pressure.
2.1.1 General: There were no significant changes in arterial
PCO^j PO^ or pH in any of the groups during infusion of the 
drug (Table 17). The PCO^ in all groups varied between 3 4 + 1  
to 3 6 + 1 ;  PO^ between 124 + 6 to 134 + 4, and the pH between 
7.419 +0.01 to 7.440 + 0.001. The infusion of a lutrol- 
glycerine-water solvent in control animals did not significantly 
change either mean arterial blood pressure or arterial plasma 
glucose.
Blood pressure: By contrast, nimodipine administration
produced a dose-dependent decrease in MABP, with the maximum 
decrease being observed at five minutes from the start of the 
infusion (Table 18, Figure 17). Thereafter the MABP rose, but 
stabilised at a level below the control value by an extent pro­
portional to the dose that was used. For example, after 15
min infusion with the lowest concentration of nimodipine (1 pg 
—1 —1kg min ) blood pressure was reduced only modestly (about 14%), 
and a similar decrease (16%) was seen at a dose of 2 pg kg  ^
min However, a dose of 4 pg kg ^min  ^reduced blood press­
ure markedly (by 26%).
A dose-dependent increase in plasma glucose was also 
observed during the infusion of nimodipine (Figure 17). An 
insignificant elevation in plasma glucose was obtained during 
(1 pg kg'^min”'*') infusion, but significant increases occurred 
with 2 pg kg’~1min”*1 (by 23%) and with 4 pg kg ^min 1 of nimo­
dipine (by 44%).
2.1.2 The effect on local CBF.
The intravenous infusion of nimodipine (1 pg kg ^min 
provoked significant increases in local CBF in 9 of the 31 
regions (including the cerebral cortex, hippocampus, hypothal­
amus and most thalamic nuclei). These changes reached signif­
icant levels (p< 0.05 or p < 0.01) with Student's t-test for 
grouped data with Bonferroni correction (Table 19). Trends 
towards an increase in CBF, which failed to reach significance 
with this conservative statistical analysis, but which would 
have attained significance (p<0.05) with uncorrected t-test, 
were noted in four brain regions (thalamus mediodorsal, septal 
nucleus, caudate nucleus and globus pallidus; Table 19).
Administration of nimodipine (2 pg kg ^min ^) increased 
significantly the local CBF in parietal cortex, sensory-motor 
cortex, auditory cortex and frontal cortex, and to a lesser 
extent in nucleus accumbens and medial geniculate.
With four-fold increase in the concentration of intra­
venous nimodipine administration (4 pg kg ^min ^) the local CBF 
was increased significantly in parietal cortex, sensory-motor 
cortex, auditory cortex and frontal cortex. Trends of increase 
in local CBF in medial geniculate, hippocampus and septal nucl­
eus were again observed.
It was noteworthy that the increases in CBF were most 
marked and the significance levels greatest during infusion of 
the lowest studied concentration of nimodipine (Table 19).
There was not a dose-dependency (i.e., with further increases 
in CBF being observed during infusion of greater concentrations 
of nimodipine) in the range studied in any region of the brain. 
For example, the CBF of the parietal cortex increased by 108%, 
91% and 80% with 1, 2 and 4 pg kg ^min ^ of nimodipine infusion,
respectively.
The effects of nimodipine in local CBF were regionally 
heterogeneous. The most marked increases in CBF (by more than 
60%) were observed in rostral neocortex; moderate increases 
(25-50%) were observed in various subcortical forebrain areas 
(caudate nucleus, globus pallidus, hypothalamus and some thal­
amic nuclei) and some components of the limbic system (hippo­
campus, septal nucleu and amygdala). In contrast to the 
increases in CBF observed in forebrain regions, there was no 
significant increase in regions of the lower brain stem, cere­
bellum and pons or in myelinated fibre tracts (Table 19).
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Time course of the effect of a continuous infusion of vehicle 
or nimodipine upon arterial blood pressure and plasma glucose. 
Data are presented as percent of pre-infusion base line value 
(mean + SE). *p<c0.05 from base line (Student's paired t-test 
with Bonferroni correction).
2.2 Effect of nimodipine on local CBF and local CGU 
relationship in conscious rats.
2.2.1 General:
There were no significant changes in PCO^, PO^ or pH 
during the administration of the drug in any of the experimental 
groups (Table 20). In groups used for measurement of blood 
flow, the PCO2 was 3 6 + 2  and 3 5 + 1  for control and nimodipine 
infusion, respectively; P0^ was 8 1 + 2  for vehicle and 8 2 + 1  
for nimodipine. The plasma glucose was 8.3 + 0.06 mM (vehicle) 
and 8.5 + 0.11 (nimodipine).
In groups used for the measurement of glucose utilisation 
(Table 20), PCO^ was 3 5 + 2  (vehicle) and 3 6 + 2  (nimodipine), 
and PO^ was 8 1 + 1  (vehicle) and 8 3 + 3  (nimodipine). Plasma 
glucose was measured as 8.4 + 0.05 nM (vehicle) and 8.3 + 0.03 
mM (nimodipine).
The infusion of a lutrol-glycerine-water solvent in control 
animals did not change the MABP significantly, whereas with nimo­
dipine (1 pg kg ^min ^) there was a small reduction in MABP (8%) 
which just failed to achieve statistical significance (Table 20).
2.2.2 Results
The effects of nimodipine infusion on local CBF and 
local CGU.
Cerebral glucose utilisation: The local CGU was measured
in 34 regions of the brain as shown in Table 21. Intravenous 
infusion of nimodipine (1 pg kg ^min *) did not alter signifi­
cantly the rate of glucose utilisation in any of the 34 regions 
of the CNS which were examined (Table 21). Even though in many 
regions there was a tendency towards slightly lower (5-10%) rates 
of glucose use during nimodipine infusion, the responses were
similar in quantitative terms, and the autoradiograms from 
nimodipine-treated rats were indistinguishable from those anim- ■ 
als which had received vehicle. Even after detailed visual 
inspection of the autoradiograms, no region could be identified 
as displaying a focal alteration in glucose utilisation.
Local cerebral blood flow: Cerebral blood flow was
~ - significantly increased during nimodipine (1 pg kg^min"*^) 
administration in 24 of 34 regions of the CNS examined (Table 
21, Figures 18-20), most notably the cerebral cortices (audit­
ory cortex, visual cortex, parietal cortex, frontal cortex and 
sensory-motor cortex), thalamus, hypothalamus, most extrapyra- 
midal regions, and some components of the limbic system such as 
the hippocampus (molecular layer) and amygdala. In a few cere­
bral structures (e.g., globus pallidus, pontine reticular form­
ation) the level of local CBF was minimally altered by nimodipine 
administration. The overall unweighted average of cerebral blood 
flow in gray matter areas was increased by 44% during the infusion 
of nimodipine.
The median alteration in local CBF provoked by nimodipine 
administration was 32%, with the proportionately greatest incr­
eases being observed in the posterior parietal cortex (increased 
by 84%), auditory cortex (by 64%), medial geniculate body (by 
61%) and sensory-motor cortex (by 50%), and the proportionately 
smallest increases being observed in the globus pallidus (3%) 
and pontine reticular formation (12%). Blood flow in each of 
the four regions of the white matter was unaltered by nimodip­
ine infusion (mean increase in CBF: 1%).
Relationship between local blood flow and local glucose
utilisation: In vehicle-treated control rats there is an
excellent correlation (pcO.Ol) between the local levels of 
blood flow and glucose utilisation (Figures 18 and 19). This 
was observed by analysis of data using linear regression; 
evaluation of the derived correlation coefficient revealed a 
close correlation between the mean levels of cerebral blood 
flow (Y) and the mean levels of glucose utilisation (X) in all 
regions of the CNS (Figure 18), the correlation coefficient to 
the least squares fit of Y = mx+b being 0.95 (p<.0.01), and m =
1.5 (ml blood/pmol glucose), with the highest levels of each 
variable being noted in cerebral cortex, thalamus and hippo­
campal formation, and the lowest values in the hypothalamus, 
amygdala and white matter (Table 21). The level of blood flow 
(ml lOOg ^min ^) was approximately 1.5 times the level of glu­
cose use (pmol lOOg 'Hnin ^) in all regions of vehicle-treated 
/
control animals. No significant inter-regional differences 
could be demonstrated in any region in the value of local flow: 
glucose ratio, using the conservative test of Greenhouse and 
Geisser (for details see McCulloch et al. 1982).
During nimodipine infusion there was a close correlation 
between local CBF and local CGU (y=mx+b), being 0.95 for both 
nimodipine and vehicle groups (p<.0.01) (Figure 18), but the 
relationship between local CBF and local CGU was re-set. Thus, 
for a given level of LCGU there was a higher level of local 
cerebral blood flow.
The disturbance of the relationship by nimodipine could 
be easily seen from the median value of the ratio of local blood 
flow to glucose use (2.5 ml.pmol ^). Although during treatment 
with nimodipine the local levels of blood flow and glucose use
generally displayed the same regional hierarchies, inter­
regional differences which just achieved statistical signifi­
cance (p<.0.05) with the test of Greenhouse and Geisser could 
be demonstrated in the local ratio of blood flow to glucose 
use. These were restricted to two regions of gray matter, 
namely sensory-motor cortex (flow:glucose ratio 3.69 ml pmol  ^
which was significantly greater than that in other areas with 
the same treatment), and globus pallidus (ratio 1.75 ml pmol \  
significantly lower than in other areas with the same treatment). 
Notwithstanding this evidence for slight regional heterogeneity 
in the local flow - glucose use relationship with nimodipine 
treatment, it should be emphasised that flow and glucose use 
remained generally strongly correlated.
Because the above data were derived from two different 
sample populations, in which two distinct measurements were made, 
the relationship between local CBF and local CGU was re-examined
using a rigorous statistical model developed by McCulloch et al.
(1982) to investigate the relationship of the average local CGU 
in different regions, but taking into account the correlation 
between observations in the same animals. The transformation 
of the data to natural logarithms of the mean values disclosed 
a linear relationship between local CBF and local CGU. This 
is characterised by unit slope and intercept ^  (Figure 20),
and the coupling between local CBF and local CGU in nimodipine
treatment is seen to be re-set towards increased values for 
cerebral blood flow at a very high level of significance (p= 0.0002).
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3. Effects of Nimodipine on Local CBF and Neuropathological
Patterns in Anaesthetised Rats following MCA Occlusion
3.1 Effect of pre-treatment with nimodipine (1 pg kg ^min 
on local CBF in rats following MCA occlusion.
3.1.1 General
There were no significant changes in the blood gas tens­
ions, plasma glucose levels and arterial pH between vehicle and 
nimodipine pre-treated groups (Table 22). The PCO^ varied 
between 39 + 1 to 40 + 1 (mm Hg), P0^ varied between 131 + 3 to 
128 + 8 (mm Hg), and pH between 7.47 + 0.01 to 7.44 + 0.01; 
plasma glucose levels (mM) varied between 9 + 1  to 1 0 + 1 .  The 
MABP (mm Hg) decreased with nimodipine infusion by 8% (Table 22); 
this failed to reach the accepted significance level.
3.1.2 Results
A. Control animals.
The level of local CBF in 34 anatomically discrete regions 
ipsilateral and contralateral to the MCA occlusion are shown in 
Table 23. Visual inspection of the autoradiograms from both 
vehicle and nimodipine groups showed marked reductions in local 
CBF in the hemisphere ipsilateral to the MCA occlusion as com­
pared to the contralateral hemisphere. Marked reductions in 
local CBF were observed throughout the cerebral cortices ipsi­
lateral to MCA occlusion: the visual cortex (by 61%), auditory
cortex (by 73%), parietal cortex (by 71%), sensory-motor cortex 
(by 78%) and frontal cortex (by 75%).
The level of blood flow was reduced massively (by 92%) 
in the caudate nucleus ipsilaterally when compared to the
contralateral side of the lesion. Modest reductions (range 
13-30%; average 22%) were observed in the ipsilateral, medio- 
dorsal and ventrolateral thalamus, medial geniculate body, 
hippocampus, dentate gyrus, amygdala, nucleus accumbens, sub­
stantia nigra compacta, and genu. The level of blood flow in 
other regions subjected to MCA occlusion were generally similar 
to those compared to the contralateral side of the lesions 
(habenula, hypothalamus, septal nucleus, vestibular nucleus, 
cochlear nucleus, superior olive, inferior colliculus, pons, 
cerebellum hemisphere, cerebellum nuclei, cerebellum white, 
corpus callosum, and internal capsule). Some regions in the 
hemisphere contralateral to the occluded vessel showed increased 
CBF levels. These regions included globus pallidus and sub­
stantia nigra (reticulata).
B. Nimodipine pre-treated groups.
The pattern of local CBF levels in regions of the CNS were 
similar to those animals receiving vehicle when comparisons are 
made between the ipsilateral and contralateral sides to the 
occluded vessels (Table 23). The administration of nimodipine 
modified the pattern of local CBF disturbances in most cortical 
and subcortical regions of the brain examined compared with the 
corresponding sites during infusion of the vehicle that were 
observed in both contralateral and ipsilateral sides.
Comparison of LCBF in contralateral hemisphere in rats
with MCA occlusion, pre-treated with nimodipine or vehicle.
Nimodipine pre-treatment at a dose of 1 g kg ^min ^ 
increased the local CBF significantly in 26 of 34 regions of 
the contralateral hemisphere (Table 23), particularly in the
neocortical areas, including visual cortex, auditory cortex, 
parietal cortex, sensory-motor cortex and frontal cortex 
(range 76-96%; average 86%). Modest increases in the local 
CBF occurred in some subcortical regions; for example, thalamus 
mediodorsal (by 56%), hippocampus (by 60%), amygdala (by 54%), 
globus pallidus and substantia nigra compacta (by 36%). The 
CBF levels were unaltered in regions which included the cere­
bellar white, corpus callosum, genu of corpus callosum, and 
internal capsule.
Comparison of LCBF in ipsilateral hemisphere in rats with
MCA occlusion, pre-treated with nimodipine or vehicle.
The ipsilateral reductions in the local blood flow obser­
ved in vehicle groups were significantly less pronounced with 
nimodipine (1 pg kg ^min ^) pre-treatment (Table 23, Figure 21). 
The main areas in which the reduction in flow was minimised were 
the cortical regions (visual cortex, auditory cortex, parietal 
cortex, sensory-motor cortex and frontal cortex). This pattern 
of increasing the flow in the hypoperfused regions (ipsilateral 
to the lesion) was also observed in some subcortical regions; 
for example, nucleus accumbens, dentate gyrus, hippocampus, 
thalamus (mediodorsal), substantia nigra (compacta), amygdala, 
and medial geniculate body. By contrast, there were no changes 
in the distribution of blood flow in the centre of the ischaemic 
lesion such as the caudate nucleus. In addition, nimodipine 
pre-treatment did not produce any changes in the level of blood 
flow in the genu of corpus callosum.
Effect of nimodipine pre-treatment on the frequency
distribution of CBF following MCA occlusion.
The frequency distribution of the level of CBF was meas­
ured bilaterally (ipsilateral and contralateral to MCA occlusion 
in animals receiving vehicle or nimodipine) in parietal cortex, 
auditory cortex, sensory-motor cortex and caudate nucleus (Figs.26,27) 
(Tables 24-27). These areas were selected to assess the influ­
ence of nimodipine pre-treatment in regions outside the centre 
of ischaemia (cortical areas) and the core of ischaemic damage 
(caudate nucleus) in rats following MCA occlusion. The analysis 
of data was performed according to the method of measuring the 
CBF frequency distribution described previously (Chapter II,
Section 2.3.2).
Both in nimodipine and vehicle groups there were signif­
icant differences between the parietal cortex, auditory cortex, 
sensory-motor cortex and caudate nucleus side ipsilateral to 
the MCA occlusion when compared to the contralateral side 
(Tables 24-27). In animals receiving vehicle, the area of 
auditory cortex with CBF less than or equal to 25 ml lOOg ^ 
min ^ was 10 + 2% (contralateral) and 20 + 3% (ipsilateral), 
and in nimodipine pre-treated animals the area of auditory cor­
tex with CBF less than or equal to 25 ml lOOg ^min ^ was 8 + 1 %  
(contralateral) and 3 + 1 %  (ipsilateral) (Table 24). A similar 
pattern of redistribution of the level of blood flow was observed 
in the other cortical areas examined (see Tables 25 and 26). By 
contrast, nimodipine pre-infusion failed to modify the level of 
blood flow in the ischaemic caudate nucleus, when comparison was 
made between ipsilateral (vehicle) to the ipsilateral side to the 
ischaemic lesion when pre-treated with nimodipine (Table 27).
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Figure 21. The white histograms represent brain regions with 
hypoperfusion ipsilateral to MCA occlusion after infusion of 
vehicle. The solid histograms are for the corresponding ipsi­
lateral areas with nimodipine pre-treatment (n=5 for each group) 
The values are mean + SE; *p<0.05; **p<0.01; ***pc0.001,
using unpaired Student's t-test.
3.2 Effect of pre-treatment with nimodipine (2 pg kg ^min
on local CBF in rats following MCA occlusion.
3.2.1 General
There were no significant changes in the blood gas tens­
ions, plasma glucose levels and arterial pH between saline and 
nimodipine pre-treated groups (Table 28). The MABP (mm Hg) 
decreased with nimodipine (2 pg kg ^min by 16% (Table 28).
3.2.2 Results
A. Control rats (receiving saline) studied after MCA
occlusion.
The level of local CBF in 34 anatomically discrete reg­
ions ipsilateral and contralateral to the MCA occlusion are 
shown in Table 29. Marked reductions in local CBF were obser­
ved throughout the cerebral cortices ipsilateral to MCA occlus­
ion, in the visual cortex by 52%, parietal cortex by 75%, 
sensory-motor cortex by 72%, and frontal cortex by 72%.
The level of blood flow was reduced massively (by 86%) 
in the caudate nucleus ipsilaterally when compared to the contra­
lateral side of the MCA occlusion. Modest reductions (range 
11-44%; average 28%) were observed in the ipsilateral thalamus 
(mediodorsal), thalamus (ventrolateral), medial geniculate body, 
lateral geniculate body, hippocampus, dentate gyrus, amygdala, 
septal nucleus, nucleus accumbens, substantia nigra (pars 
compacta) and genu of the corpus callosum. The levels of 
blood flow in other ipsilateral brain regions were generally 
similar to those in the hemisphere contralateral to the lesion. 
These regions were the habenula, hypothalamus, vestibular nucleus, 
cochlear nucleus, superior olive, inferior colliculus, pons,
cerebellum hemisphere, cerebellum nuclei, cerebellum white, 
corpus callosum and internal capsule.
B. Animals pre-treated with nimodipine before MCA occlusion.
When comparisons were made of the effects of nimodipine 
in contralateral hemisphere with the data from control rats, it 
was found that nimodipine pre-treatment at a dose of 2 jig kg ^ 
min ^ increased the local CBF significantly in 10 regions 
(Table 29). These included the auditory cortex (by 37%), 
parietal cortex (by 48%), sensory motor-cortex (by 50%) and 
frontal cortex (by 50%). Increases in the level of CBF were 
also observed in some subcortical regions; for example, medial 
geniculate body (by 36%), lateral geniculate body (by 40%), 
hippocampus (by 44%), dentate gyrus (by 35%), caudate nucleus 
(by 44%) and nucleus accumbens (by 51%). When the hemisphere 
ipsilateral to occlusion was studied, it was seen that the 
administration of nimodipine modified the pattern of local CBF 
disturbances in most of the cortical and subcortical regions 
affected by MCA occlusion. Compared with the controls, the 
reduction in the local CBF observed after pre-treatment with 
nimodipine was significantly less; that is, the LCBF in the 
ipsilateral hemisphere was higher than after occlusion in 
untreated animals (Table 29). The main areas in which the 
reduction in flow was minimised were the cortical regions, 
auditory and parietal cortices; for example, in parietal cor­
tex the value without pre-treatment was 3 9 + 6 ,  and after pre- 
treatment was 97 + 10, compared with value in contralateral 
hemisphere in untreated rats (156 + 10). The values observed 
were, untreated 75% and treated 38%, and the latter was 58% of 
the value of the contralateral hemisphere in treated rats.
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3.3 Effect of pre-treatment with nimodipine (1 pg kg ^min 
on neuropathological patterns in rats following MCA 
occlusion.
3.3.1 General
There was not a significant difference between the blood 
gas tensions, plasma glucose levels and arterial pH between 
vehicle and nimodipine pre-treated groups (Table 30); PCO^ 
range 3 9 + 1  to 40 + 1, PO^ range 131 + 5 to 140 + 4, pH range 
7.42 + 0.01 to 7.44 + 0.02, and plasma glucose levels - range 
9 + 1 to 10 + 1.
In the animals that received vehicle there was not a sig­
nificant alteration in the MABP values as compared with the base 
line level (Table 30). However, in nimodipine treated animals, 
throughout the infusion period of the drug (Table 30), there was 
a small reduction (7%) in the MABP, which did not reach a signif­
icant level when compared with the base line value.
3.3.2 Effect on the neuropathological pattern
The amount of ischaemic damage in the hemisphere, cortex 
and caudate nucleus was measured according to Graham et al.
(1984) (see Chapter II, Section 5). The area of ischaemic 
damage in the hemisphere, cortex and caudate nucleus in control 
and nimodipine pre-treated animals is shown in Figures 22-24. 
There was extensive ischaemic damage in the ipsilateral neo­
striatum of all the animals with MCA occlusion. Comparisons 
of the distribution of the ischaemic lesion at each stereo­
tactic level showed that the damage was less extensive in rats 
treated with nimodipine as compared with the control rats 
(Figures 22, 23). The volumes of ischaemic damage in the 
hemisphere, cortex and caudate nucleus in vehicle receiving
animals and nimodipine pre-treated animals after MCA occlusion
are shown in Figure 25. The volume of hemispheric damage was
3 3
reduced from 47 + 7 mm to 31 + 3 mm in nimodipine pre-treated
rats. The volume of cortical damage was reduced from 2 6 + 6
3 3mm with vehicle to 16 + 3 mm with nimodipine.
Although nimodipine pre-treatment produced a marked
reduction in the volume of ischaemia, this just failed to reach
the accepted significance level when treated by Student's t-test.
This may be explained by the fact that there was considerable
inter-animal variability of presence of ischaemic damage when
the middle cerebral artery occlusion was performed. However,
a trend towards- a beneficial effect of the drug in minimising
the volume of ischaemic infarct can be observed (Figure 25).
By contrast, there was not a significant difference in the
effect of nimodipine on the volume of ischaemic damage in the
3
caudate nucleus which was, with nimodipine, 13 + 2 mm compared
3
with 15 + 2 mm with vehicle (Figure 25).
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Figure 22.
Ischaemic Damage in Cerebral Hemisphere 
Nimodipine Pre-Treatment
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ally determined positions in the cerebral hemisphere for 
vehicle (control n=8) and nimodipine pre-treated (n-8) 
animals; unpaired Student's t-test; M + SE; *p<0.05.
Figure 23.
Ischaemic Damage in Cerebral Cortex 
Nimodipine Pre-Treatment
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Figure 24.
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Ischaemic Damage in Caudate Nucleus 
Nimodipine Pre-Treatment
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Figure 25.
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3.4 Effect of post-treatment with nimodipine (1 yg kg ^min
on local CBF in rats following MCA occlusion.
3.4.1 General
The cardiovascular and respiratory status of the control 
and the nimodipine treated animals is shown in Table 31. The 
MABP at the time of CBF measurement (i.e., 30 min after nimod­
ipine infusion was started) was significantly lower in the drug 
treated group than in the control. Otherwise, there was not a 
statistically significant difference between the two groups.
3.4.2 Effect of nimodipine on local CBF after MCA occlusion.
The levels of CBF in 35 neuroanatomically defined brain
areas after 35 min of ischaemia are shown in Table 32. Both 
in the control and the drug treated groups, marked reductions 
in CBF were observed throughout the ipsilateral neocortex and 
the lateral neocortex, and the lateral neostriatum. There 
were also significant reductions in the ipsilateral cingulate 
cortex, nucleus accumbens, septal nucleus, ventral thalamus, 
amygdala, and medial neostriatum. Increases in CBF were 
observed in the ipsilateral globus pallidus and substantia 
nigra, but these increases achieved statistical significance 
only in the nimodipine treated animals. In the majority of 
the brain structures, including brain stem and cerebellum, CBF 
values were symmetrical.
The administration of nimodipine, initiated five minutes 
after MCA occlusion, did not modify the pattern of CBF disturb­
ance in the territory of the occluded vessel, nor in any adjacent 
or distant area. The values of CBF both ipsilateral and contra­
lateral to MCA occlusion were similar in the vehicle and nimod­
ipine treated groups.
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CHAPTER IV 
DISCUSSION
1. The Effects of Nimodipine Administration in LCBF in
Anaesthetised Animals, and the Relationship between 
LCBF and LCGU in Conscious Animals.
1.1 The effects of nimodipine on LCBF in anaesthetised
animals: relationship to arterial blood pressure.
The effects of nimodipine and other calcium antagonists 
on CBF have been extensively investigated in primates, dogs, cats, 
rats and man under conditions in which the cerebral circulation 
was intact (Harper et al. 1981; Kazda et al. 1982; Edvinsson 
et al. 1983; Haws et al. 1983; Hav/s and Heistad, 1983; McCalden 
et al. 1984) and with pre-existing cerebrovascular dysfunction 
(Hiffmeister et al. 1979; Gaab et al. 1982; Harris et al. 1982; 
Karasawa et al. 1982; Symon et al. 1982; Allen et al. 1983;
Gygax and Wiernsperger, 1983; Faden et al. 1984; Newberg et al. 
1984). No consensus has yet been established as to whether calc­
ium antagonists, which are certainly potent dilators of cerebral 
vessels, do indeed increase CBF.
In the first part of this study three factors were 
addressed: the complicating actions of the drug on arterial
pressure, the dose dependency, and regional heterogeneity in 
the cerebrovascular response.
The effects of nimodipine on MABP may have been an important 
factor on the cerebrovascular effects of the drug. Even with 
the lowest concentration of nimodipine studied (1 pg kg”^min~^) 
blood pressure was reduced modestly {rv14%), and pronounced 
increases in CBF in rostral brain areas were observed. A 
four-fold increase in the infusion concentration reduced blood
pressure markedly (by 26%) and produced no further increase 
in CBF. The reason that increasing concentrations failed 
to provoke a further increase in CBF may have been because 
of the concomitant hypotension. This is analogous to the 
attenuation of hypercapnic cerebrovascular dilatation by hypo­
tension (Harper and Glass, 1965). Although the interaction . 
of two dilator stimuli (nimodipine and hypotension) may be a 
complicating factor in investigations in animals or humans with 
normal autoregulation, the effects of nimodipine in patients 
with impaired autoregulation, such as those with cerebrovasc­
ular disease (Overgaard and Tweed, 1974, 1983; Fitch et al. 
1976; Kosnik and Hunt, 1976; Ledingham and Rajagopalan, 1979) 
may depend crucially on the effects of the drug on perfusion 
pressure. Thus, the hypotension produced by nimodipine may 
be deleterious in patients with impaired autoregulation or 
whose cerebral resistance vessels are already maximally dilated.
In any studies of cerebral blood flow, either in normal 
or in damaged brain, the choice of method of measurement has 
important implications. Each technique has particular advant­
ages and disadvantages, which limits its use, even in specific
133experimental situations. The Xenon clearance technique 
(HgSedt-Rasmussen et al. 1966; Harper et al. 1972) should be 
used in primates, and not in dogs or cats in whom the brain 
is supplied both by the internal and external carotid arteries. 
Thus, it is difficult to avoid extracranial contamination. 
Multiple serial measurements can be obtained by this technique;
in addition, metabolic studies are possible.
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The Krypton clearance technique (Harper et al. 1961; 
Ingvar and Lassen, 1962) allows repetitive measurements of flow 
of the cortical gray matter in all species. However, the
Krypton is a beta-emitting isotope and therefore requires 
surgical exposure of the cortex to avoid absorption of radio­
activity by the skull. The microsphere trapping method 
(Marcus et al. 1976) can be used in any animal, and allows 
three to six flow measurements in multiple anatomically gross 
regions in the same animal. The major advantage of this tech­
nique is the possibility to measure the flow of the brain and 
other organs (for example, heart, kidney), and the same tissue 
sample which is used for flow measurements may also be assessed 
for tissue constituents (for example, water, electrolytes or 
biochemical substrates). However, the incomplete mixing or 
streaming of microspheres can produce artefacts. The hydrogen 
clearance technique (Pasztor et al. 1973) permits repeated flow 
measurements at multiple sites, but requires insertion of elec­
trodes into the brain, and a traumatic effect may be difficult 
to avoid. Moreover, the choice of sites is limited.
In the present studies, cerebral blood flow was measured 
using the quantitative autoradiographic technique described by 
Sakurada et al. (1978). The benefits of this method are that 
it allows blood flow measurement in multiple, anatomically dis­
crete regions; of the brain in any animal. One limitation is
that measurements can only be made once per animal. A major 
14
advantage of the C-iodoantipyrine technique (Sakurada et al.
1978) is that it complements the autoradiographic technique for 
measuring the local cerebral glucose utilisation (Sokoloff et 
al. 1977), and this provides the technical capacity for rigor­
ous investigations of the relationship between blood supply and 
metabolic demand.
The inter-regional differences in the cerebrovascular 
response to nimodipine administration have not been studied in
detail previously. Haws et al. (1983) examined, with radio­
active microspheres, the effects of nimodipine in five gross 
anatomic regions of rabbit brain (cortex, caudate, brain stem, 
cerebellum and white matter) and observed proportionately simi­
lar elevations in each region after nimodipine administration.
T 14 1
In the present study, using [_ CJ-iodoantipyrine autoradiography 
to assess CBF at a large number of well-defined neuroanatomical 
locations, there was a clear regional heterogeneity in the alter­
ation in local CBF provoked by nimodipine administration.
There were clear rostro-caudal differences in the cerebro­
vascular effects of nimodipine, with marked increases in CBF 
rostrally and minimal changes caudally. Thus, the most marked 
increases in CBF (by more than 60%) were observed in the rostral 
neocortex (parietal, auditory, sensory-motor and frontal cortices); 
moderate increases (25-50%) were observed in various subcortical 
forebrain regions (caudate nucleus, globus pallidus, hypothalamus 
and some thalamic nuclei) and some components of the limbic system 
(hippocampus, septal nuclei and amygdala). In sharp contrast, 
blood flow in the cerebellum, lower brain stem and white matter 
was minimally altered by the infusion of nimodipine (Table 19).
The difference between these findings and the rather homogeneous 
elevations of CBF described by Haws et al. (1983) may reflect 
better spatial resolution provided by 
compared to microspheres.
In addition, the same group demonstrated no change in CBF 
following nimodipine administration, and showed that the drug 
inhibits autoregulation of cerebral blood flow in response to 
hypertension in anaesthetised cats or monkeys (Haws and Heistad, 
1984). This is in contrast to previous studies (Harris et al 
1982; Symon et al. 1982; McCalden et al. 1984) in which nimodipine
K l - iodoantipyrine as
was found to have little effect on autoregulation during change 
in arterial blood pressure in baboons. The reason for the 
reported differences in direct effects of nimodipine on CBF in 
the two studies from the same group (Haws et al. 1983; Haws 
and Heistad, 1984) is not clear; they used the same method of 
measurement of blood flow (radiolabelled microsphere) and the 
same dose of nimodipine. This discrepancy in their data may 
be attributed to difference in species (rabbit: Haws et al.
1983; cats and monkeys: Haws and Heistad, 1984). It is more
likely that it is explained by the differences in experimental 
design. In their later studies in cats and monkeys, half of 
the control measurements of CBF were obtained 1-2 hours after 
stopping nimodipine infusion. It should be noted that the 
biological half-life (t^) of nimodipine is relatively short, 
and is reported to be about 10 min in the baboon (Harris et al.
1982).
1.2 The effects of nimodipine on LCBF and LCGU in
conscious animals.
In normal brain there is a close association, globally 
and locally, between the level of CBF and the level of energy 
generation. The latter is almost exclusively derived from the 
oxidative catabolism of glucose (Edvinsson and Mackenzie, 1977; 
Kuschinsky and Wahl, 1978; Siesjo, 1978; Kuschinsky, 1982-1983). 
It is increasingly recognised that effects on cerebral tissue 
metabolic activity are often the primary mechanism underlying 
the alterations in CBF that result from the administration of 
neurotransmitters or drugs. Although the direct actions of
calcium antagonists on the cerebral vasculature have been invest­
igated extensively (Allen and Bahr, 1979; Allen and Banghart, 
1979; Edvinsson et al. 1979; White et al. 1982; Andersson et 
al. 1983; Auer et al. 1983; Brandt et al. 1983), there have 
been no complete systematic investigations of cerebral glucose 
utilisation.
It has been shown that nimodipine increased hemispheric 
blood flow significantly, but had no effect on cerebral oxygen 
uptake and no obvious increase in electrocortical activity 
(Harper et al. 1981). These observations have been confirmed 
by several studies (Kazda et al. 1982; Haws et al. 1983;
Steen et al. 1983; McCalden et al. 1984). Two lines of 
evidence indicate that calcium antagonists may have actions 
on cerebral tissue distinct from their effects on cerebral 
vessels. Firstly, several workers have demonstrated the 
presence of high-affinity binding sites for nimodipine and 
other dihydropyridine calcium antagonists in CNS as well as 
other tissues (cardiac, skeletal and smooth muscle), and there 
is good evidence to believe that these highly specific binding 
sites, at least in peripheral tissue, represent the locus of 
action of calcium antagonists (Bellemann et al. 1982; Bolger 
et al. 1982; Ehlert et al. 1982; Fairhurst et al. 1983;
Murphy and Snyder, 1982; Peroutka and Allen, 1983; Luchowski 
et al. 1984). Autoradiographic studies with ^H^-dihydropyrid- 
ine agents suggest that the density of binding in synaptic areas 
of the brain is much greater than in blood vessels (Quirion, 1983; 
Ferry et al. 1984). Secondly, the administration of calcium 
antagonists can produce overt, though subtle, alterations in 
behaviour (Hoffmeister et al. 1982; Shah et al. 1983), and
changes in cerebral fucntion are generally reflected in local 
alterations in cerebral metabolic activity (Sokoloff, 1981a,b,
1982; McCulloch, 1982).
In the present study, the relationship between local CBF 
and local cerebral glucose utilisation was studied at only one 
dose level of nimodipine (1 pg kg ‘Snin ^), as this dose has been 
shown to have nearly maximal effects on local CBF with minimal 
effects on arterial blood pressure (McCalden et al. 1984; Mohamed 
et al. 1984) and plasma glucose concentration (Mohamed et al. 1984). 
The infusion of nimodipine at this concentration produced only a 
small (8%) reduction in the MABP which failed to reach statistical 
significance. The administration of nimodipine did not alter 
significantly the rate of glucose utilisation in any of the reg­
ions examined. By contrast, in 24 regions CBF was increased 
significantly by 39-84% from control level (for example, cerebral 
cortices, hippocampus, hypothalamus and most thalamic nuclei). 
Bellemann et al. (1983) identified the high affinity of binding 
receptors for nimodipine. They reported that the cerebral cor­
tex and hippocampus are rich in binding sites for nimodipine, 
whereas the region of the pons is a poor source of radiolabelled 
calcium antagonists. The present data showed the LCBF in cere­
bral cortices increased significantly, 84% in parietal cortex 
and 64% in auditory cortex, whereas the LCBF in pons increased 
by 12% but did not reach statistically significant level. In 
vehicle treated animals there was an excellent correlation 
(p<0.01) between the local levels of CBF and glucose utilis­
ation where the ratio of flow to .glucose use was approximately
1.5 ml pmol ^ in each brain region. During nimodipine treatment 
there was a similarly excellent correlation ( p < 0.01) between
LCBF and LCGU, but the median ratio between local flow and glu-
As shown in the present investigation, nimodipine at an 
infusion concentration with marked cerebrovascular effects did 
not alter the rate of glucose utilisation in any CMS region.
technique to map functional events in the CNS as they are 
reflected in local rates of glucose utilisation (McCulloch,
1982; Sokoloff, 1982), the findings provide no evidence that 
nimodipine has other than minimal effects on functional activ­
ity in cerebral tissue, at least under the conditions of the 
present study. • However, under the same conditions, nimodipine 
effected marked increases in CBF in most CNS areas, and the 
magnitude of the local flow changes observed is in general 
accord with those observed with previous, more global measure­
ments (Harper et al. 1981; Kazda et al. 1982; Haws et al.
1983; McCalden et al. 1984).
In sharp and puzzling contrast to the findings of the 
present study (see also Mohamed et al. 1983, 1985) is the report 
by D'Avella et al. (1984) that nimodipine at a dose of 2 yg kg  ^
increased the LCGU (measured by the (34cJ-2-deoxyglucose tech­
nique) in twenty anatomically discrete regions of the CNS.
These areas included the cerebellar hemisphere (by 191%), cere­
bellar nuclei (by 104%), visual cortex (by 118%), cerebellar 
white matter (by 96%) and corpus callosum (by 99%). There 
were no changes in the behaviour of the animals, even although 
these changes in LCGU are as great as those found in seizure 
activity by other authors (Collins, 1978; Caveness et al. 1980; 
Ingvar and Shapiro, 1981; Ingvar and Siesjo, 1983). We have
cose use increased to 2.5 ml pmol
In view of the proven utility
repeated in our laboratory the experimental protocol of D'Avella 
et al. (1984), and nimodipine failed to find any increases in 
the level of LCGU in any region of the CNS after a bolus of 
nimodipine (2 pg kg ^).
Under normal conditions, an excellent correlation exists 
between the local levels of CBF and the local rates of glucose 
utilisation in all regions throughout the CNS (Sokoloff, 1981b,c). 
In many pharmacological and pathological states, the relation­
ship between local flow and glucose use is maintained, and the 
ratio of blood flow to glucose utilisation remains unaltered in 
all areas. Alternatively, this can be demonstrated as no change 
in the intercept, oC, of the log - log glucose use - CBF plots 
(Figure 20), or as no change in the slope derived from linear 
regression analysis of glucose utilisation (Figure 18). Under 
these conditions of unaltered flow-metabolism coupling, observed 
changes in CBF are usually attributed to concomitant alterations 
in underlying cerebral metabolic activity, implicating cerebral 
tissue and not cerebrovascular smooth muscle as the primary site 
of drug action. The type of response where the flow - glucose 
use relationship is undisturbed has been observed previously 
with barbiturates (Sokoloff, 1981a), the dopamine receptor agon­
ist, apomorphine (McCulloch et al. 1982), and the ^-aminobutyric 
acid receptor agonist, muscimol (Kelly and McCulloch, 1983a).
In the second pattern of response, either the relationship 
between flow and glucose use is significantly disturbed highly 
focally in a restricted number of regions in pathological cond­
itions, such as in the vicinity of brain tumours (Blasberg et 
al. 1981; Mies et al. 1981), in cerebral ischaemia (Pulsinelli 
et al.1982b), or following administration of convulsants (Celik 
et al. 1982; Ingvar and Siesjo, 1983); or the disturbance of
the flow - glucose use relationship is widespread throughout 
the CNS. In these cases there is often an excellent corre­
lation between flow and glucose use, but a marked alteration, 
in almost every region, in the magnitude of the ratio of blood 
flow to glucose use. This type of response has been noted 
previously with indomethacin, where the ratio of flow to glu­
cose use is reduced throughout the brain (Pickard, 1981), with 
chronic metabolic acidosis, with noradrenaline-induced hyper­
tension, and with tf-hydroxybutyrate administration, where the 
flow to glucose use ratio throughout the brain is increased 
(Kuschinsky et al. 1981, 1982, 1983, 1985). The changes in 
the flow - glucose use relationship that resulted from nimodip­
ine administration are of this latter type, and the rather 
homogeneous alteration of this relationship throughout the CNS 
implicates a nimodipine-sensitive process (almost certainly 
calcium influx into cerebrovascular smooth muscle) (Bolton,
1979; Cauvin et al. 1982, 1983; Kawaguchi et al. 1982; Pan and 
Janis, 1984) as an integral component of the normal mechanisms 
via which blood flow is adjusted in vivo.
Evidence that nimodipine is beneficial in the treatment 
or prevention of cerebrovascular diseases is at present not 
conclusive. There are clinical reports that nimodipine may 
be of benefit in the prevention of vasospasm following a sub­
arachnoid haemorrhage and, in these circumstances, may elevate 
CBF in patients (Brawanski et al. 1982; Gaab et al. 1982;
Allen et al. 1983; Gelmers, 1982, 1984). Furthermore, Auer 
et al. (1983) have shown that nimodipine may dilate cerebral 
blood vessels in patients during extracranial-intracranial 
bypass surgery. What has not been established is whether 
these drugs will be more effective in the prophylaxis than in
the treatment of established brain damage. The results of 
the first part of the present studies clearly emphasise that, 
whatever the disease, the dose must be regulated very carefully 
to avoid hypotension and hyperglycaemia; with calcium antagon­
ists, correct dose selection may therefore be critical. In 
addition, the observation that the increases in CBF produced 
by nimodipine are not associated with any potentially damaging 
increases in cerebral metabolism may be an important element in 
the use of drugs such as nimodipine in the treatment of cerebro­
vascular disease. The aim of the second part of this thesis 
was to determine the effects of nimodipine in a well defined 
experimental ischaemic insult.
2. The Effects of Nimodipine on a Focal Ischaemic Lesion.
2.1 The effect of nimodipine pre-treatment on LCBF
following MCA occlusion.
i
One common cause of stroke in man is the occlusion of a 
brain vessel, usually arterial, or the spontaneous rupture of 
an intracranial artery with consequent haemorrhage in the brain 
parenchyma or in the subarachnoid space (Walker and Marx, 1981).
A major consideration in the evaluation of experimental models 
of ischaemic stroke in animals is the clinical relevance of the 
models. Waltz'(1979) has suggested that the proximal MCA 
occlusion is probably equivalent to a large cerebral infarct 
in man.
A wide variety of experimental models of cerebral ischaemia 
are available: global cerebral ischaemia has been performed by
asphyxiation (Meyer, 1958; Cantu et al. 1969; Ames, 1975; 
Reichman, 1976); hemispheric ischaemia can be produced by 
ligation of the internal carotid artery or by injection of large 
emboli via the carotid artery (Fisher, 1951; Brown and Brierley, 
1973; Molinari et al. 1974; Levinthal et al. 1979); multifocal 
cerebral ischaemia can be induced either by microspheres or auto- 
logus blood clot injection (Penry and Netsky, 1960; Rumbaugh et 
al. 1968; Bremer et al. 1975); focal cerebral ischaemia has 
been performed by occlusion of the middle cerebral artery in 
various experimental animals, such as primates (Crowell et al.
1970; Hudgins and Garcia, 1970; Ginsberg and Myers, 1972;
Garcia, 1973; Aoyagi et al. 1975; Kawamura et al. 1975; Symon 
et al. 1979), cats (O'Brien and Waltz, 1973; Hayakawa and Waltz,
1975; Heiss et al. 1976; Katzman et al. 1977; Tamura et al.
1979), and dogs (Molinari and Laurent, 1976).
More recently, Tamura et al. (1981a) and Tyson et al. 
(1984) have described a technique for occluding the MCA in rats. 
The rat model has many advantages. There are close similarities 
between the anatomy of the cranial circulation of the rat and man 
(Yamori et al. 1976), and there is considerable information about 
various neurotransmitter systems, neurochemistry, neuroanatomy 
and neuropharmacology of the rat brain (Iversen et al. 1978; 
Roberts et al. 1978; Siesjo, 1978; Brown and Cooper, 1979). 
Also, it is in the rat, as a result of technical innovations, 
that a number of reliable quantitative techniques have become 
available that allow the regional assessment of cerebral blood 
flow (Sakurada et al. 1978), the permeability of the blood-brain
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barrier (Blasberg et al. 1978; Ohno et al. 1978), and the rates 
of cerebral glucose utilisation (Sokoloff et al. 1977) and pro­
tein synthesis (Smith et al. 1980).
The production of ischaemic damage by MCA occlusion 
(Tamura et al. 1981a) does not depend on combining arterial 
occlusion with hypoxia (Levine, 1960; Brown and Brierley, 1968; 
Salford et al. 1973), hypotension (Eklof and Siesjo, 1972; 
Nordstrom and Rehncrona, 1977) or upon anatomical variations of 
the circle of Willis (Levine and Payan, 1966; Levy et al. 1975). 
Furthermore, in this study the use of quantification methods for 
measuring the amount of ischaemic damage has been shown to be 
reproducible (Graham et al. 1984) and to have advantages over 
the techniques such as grid planimetry (Sundt and Waltz, 1967; 
Michenfelder et al. 1976). However, the occlusion of an intra­
cranial artery involves opening of the skull and subarachnoid 
space; thus, it could produce local brain damage.
The potency of calcium antagonists in preventing and 
reversing the contraction of cerebrovascular smooth muscle has 
resulted in great interest in the potential use of this group 
of compounds in the treatment of cerebrovascular disease.
Calcium antagonists have a variety of physiological 
effects that, on theoretical bases, may prove therapeutically 
effective in ischaemic brain. These include enhancement of 
CBF (Harper et al. 1981; Symon et al. 1982; Haws et al. 1983) 
selective dilatation of cerebrovascular vessels (Allen and Bahr 
1979; Allen and Banghart, 1979; Shimizu et al. 1980; Brandt 
et al. 1983; Takagi et al. 1983) and inhibition of vascular 
contraction due to substances such as serotonin (Brandt et al. 
1981a,b; Kazda and Towart, 1981; Towart, 1981).
The effect of nimodipine on blood glucose level may also 
be important. Myers (1979) showed that the recovery following 
ischaemia was influenced by the plasma glucose level. it was 
observed that if animals were fed or infused with glucose prior 
to induction of ischaemia, recovery was adversely affected. 
These observations have been confirmed by several groups 
(Siemkowicz and Hansen, 1978; Ginsberg et al. 1980; Rehncrona 
et al. 1980, 1981; Welsh et al. 1980; Kalimo et al. 1981). 
Thus, there is experimental evidence that hyperglycaemia may 
be harmful in cerebral ischaemia (Gardiner et al. 1982; 
Pulsinelli et al. 1982a). In the first part of the present 
study a dose-dependent increase in plasma glucose level was 
observed during infusion of nimodipine (increased by 44 + 2% 
after 30 min of nimodipine, 4 jig kg **min ^). The elevated 
plasma glucose concentration during nimodipine therapy, first 
noted in the present study, may counteract any beneficial 
vascular effects either in animal models of cerebral ischaemia
or in patients with cerebrovascular disease.
In the investigations involving nimodipine pre-treated 
animals, the flow values in the hemisphere contralateral to 
MCA occlusion were greater than those in corresponding sites 
in vehicle treated rats by a factor very similar to that
\
observed in normal rats. This indicates that the experimental 
lesion did not impair general cerebrovascular reactivity. In 
the hemisphere ipsilateral to the MCA occlusion, the control 
rats showed an area of profound ischaemia which conformed to 
the pattern previously described in this model (Tamura et al. 
1981a,b; Tyson et al. 1984).
Inspection of the autoradiograms and analysis of the 
measurements of local cerebral blood flow showed that nimodipine 
pre-treatment significantly lessened the fall in local CBF in 
the peripheral part of the ischaemic area of the cortex. Thus, 
in visual cortex, a region supplied by both middle and posterior 
cerebral arteries, LCBF in the occluded hemisphere of control 
rats fell to 40% of that in the contralateral hemisphere, but 
in nimodipine pre-treated rats the LCBF remained at 91% of the 
value in the contralateral hemisphere in control rats. Even 
in sensory-motor cortex, the area of deepest cortical ischaemia, 
local CBF in nimodipine treated rats was twice that of vehicle 
treated rats ( 6 1 + 9  versus 30 + 3 ml lOOg ^min ^). By con­
trast, nimodipine preloading did not influence local CBF in the 
neostriatum, the area of maximum ischaemia. This may relate to 
anatomical blood supply consideration; middle cerebral artery 
originates from the circle of Willis near the junction with the 
internal carotid artery. A few millimetres distally, it gives 
off several ascending branches to the basal ganglia (lenticulo- 
striatal arteries). Since the branches to the basal ganglia
are end-arteries, collateral blood supply is small, particularly 
when the occlusion is proximal to the point of branching, i.e., 
the occlusion includes the lenticulo-striate artery. One would 
expect, therefore, the lack of effect of nimodipine upon blood 
flow in the neostriatum is presumably because of the poor collat­
eral supply to this region. Here, compared to local CBF in the 
contralateral hemisphere of control rats, flow was reduced by 
93% in both treated and control groups. Nevertheless, there 
were no areas of the brain in treated rats that showed values 
lower than control rats. Despite the powerful vasodilatory 
effects of nimodipine, it did not cause an intracerebral steal 
effect.
In the introduction (Chapter I, Section 8) it was pointed 
out that a vasodilator could have several effects in the presence 
of a focal ischaemic lesion. These^include: 1) generalised
increase in CBF both in ischaemic and "normal" areas; 2) a 
deleterious redistribution, or steal; and 3) a beneficial 
redistribution. A consideration of the frequency distributions 
of blood flow suggests that it is the first of these three that 
best explains the effects of nimodipine pre-treatment observed 
in this study.
The frequency distribution of the level of CBF was meas­
ured bilaterally (ipsilateral and contralateral to MCA occlusion 
in animals receiving vehicle or nimodipine) in the total area of 
the hemisphere at the level of the sensory-motor cortex. Nimo­
dipine had similar effects upon the ischaemic area and the total 
hemispheric blood flows (Figures 26 and 27). For example, in 
animals receiving vehicle, the total hemispheric area with blood 
flow less than or equal to 25 ml lOOg ^min ^ was 8 + 2 %  (contra­
lateral) and 4 6 + 3  (ipsilateral), and in nimodipine pre-treated
animals the area of hemisphere with blood flow less than or 
equal to 25 ml lOOg ^min 1 was 5 + 1 %  (contralateral) and 29 
+ 6% (ipsilateral); therefore, in both vehicle and nimodipine 
treated animals the area with CBF less than or equal to 25 ml 
lOOg ^min ^ in ipsilateral hemisphere was some six-fold greater 
than that in the contralateral hemisphere. Furthermore, the 
median hemispheric blood flow in animals receiving vehicle was 
28 ml lOOg "Snin 1 (ipsilateral) and 105 ml 100g"*'Lmin-^ (contra­
lateral), and in nimodipine pre-treated groups was 46 ml lOOg”1
—1 —1 —1min (ipsilateral) and 169 ml lOOg min (contralateral).
The ratio of median values of CBF in the ipsilateral and contra­
lateral hemispheres is, therefore, 73% in both vehicle and 
nimodipine treated animals.
The pattern of local CBF in focal ischaemia is determined 
by several factors (Tyson et al. 1984). It is not possible from 
the present study to identify precisely the reason for the effects 
of nimodipine on this pattern. The beneficial effect upon flow 
in the periphery of the ischaemic cortex implies that nimodipine 
pre-treated animals were better provided with collateral supply 
to those areas. It is not clear why pre-treated animals had a 
more efficient collateral input than that evoked by the ischaemic 
insult alone, although it is tempting to invoke an action of 
nimodipine in preventing the vasoconstriction that occurs in 
focal ischaemia (Teasdale et al. 1983). This would need to 
be confirmed by direct observation. Indeed, reversal of such 
vasoconstriction, which occurs only in the area of maximum 
ischaemia, might be expected to provoke a steal effect. The 
absence of steal effect in this study may indicate that this 
occurs only when vasodilator is administered after the initial 
haemodynamic effects of local occlusion have been established.
Although the beneficial effects of pre-treatment with 
nimodipine may result from several factors, it is most likely 
due to better oxygen delivery to areas of peripheral ischaemia 
as a consequence of the relative preservation of blood flow.
The present results do not point to there having been an 
attenuation of ischaemic damage by modification of more subtle 
biochemical events, such as by the prevention of the entry of 
calcium into damaged neuron, but neither do they disprove it.
2.2 The effect of nimodipine post-treatment on LCBF
following MCA occlusion.
The results of the commencement of nimodipine (1 jig kg ^ 
min after the production of a focal ischaemic lesion showed
that the drug did not have beneficial effects on CBF. These 
findings, therefore, are in sharp contrast with the effect of 
nimodipine (1 or 2 pg kg ^min infused before middle cerebral 
artery occlusion.
The effect of the drug may be completely different depend­
ing on whether it is given before or after ischaemia, because 
different pathomechanisms of cell damage might be operating at 
different stages of ischaemia, and because changes in peripheral 
vascular tone and reactivity can occur after obstruction of a 
major cerebral artery (Waltz and Sundt, 1967; Symon et al. 1971; 
Symon et al. 1976; Teasdale et al. 1983).
The drug was infused for a total of 60 minutes before the 
CBF measurement in pre-treated animals, but only for 30 minutes 
in those post-treated groups. This may have led to different 
plasma concentrations of nimodipine at the time of the CBF 
measurement in the two groups but, in practice, the difference
is unlikely to be great. From the pharmacokinetic model (see 
Figure 2), it can be seen that the arterial plasma concentrat­
ion of nimodipine (1 jig kg ^min reaches its plateau level 
after 133 minutes of continuous infusion. After 30 and 60 
minutes of infusion, the arterial plasma concentrations of 
nimodipine are calculated to be 65% and 88% of the plateau 
level, respectively. The lower levels of systemic arterial 
blood pressure noted at the time of CBF measurements in post- 
treated animals (see Table 31) suggest that the circulating 
concentrations of the drug were sufficient to dilate peripheral 
vessels (Tanaka et al. 1980; Auer et al. 1982), which are 
generally less sensitive to calcium antagonists (Towart and 
Kazda, 1980; Brandt et al. 1981a). Moreover, the low level 
of local blood flow, with its slow delivery of the drug to the 
ischaemic area, may also be a limitation of post-treatment as 
compared to effective preloading of the brain with nimodipine 
prior to the ischaemic insult.
Another factor which may limit the effects of post- 
treatment is the profound alterations in the reactivity of 
cerebral vessels that occur during ischaemia. Indeed, as 
well as impairment of CO^ reactivity (Hossmann et al. 1973;
Symon et al. 1974) after MCA occlusion, the vasodilatory res­
ponse of pial arterioles to locally applied calcium antagonists 
is reduced (Brandt et al. 1983). it is, therefore, quite poss­
ible that the cerebrovascular response to systemically adminis­
tered nimodipine differs according to whether it is given before 
or after occlusion.
The same factors that may have limited the effect of the 
drug on the ischaemic hemisphere when given after occlusion may 
also have been responsible for the finding that blood flow was
not increased in the opposite hemisphere. However, another 
mechanism that might have reduced cerebrovascular reactivity 
in that hemisphere is the phenomenon of so-called diaschisis 
(Monakow, 1941). Tanaka et al. (1980) have shown that CBF 
is indeed reduced in areas remote from the ischaemic lesion. 
These effects would have been more extensive in post-treated 
animals than in the pre-treated series. In any event, the 
present findings raise the possibility that nimodipine may be 
"protective", but not that it is "resuscitative".
2.3 The effect of nimodipine pre-treatment on the
pathological consequences.
In this model, flow levels of less than 30 ml lOOg ^min ^ 
are associated with the development of ischaemic damage (Tamura 
et al. 1981b; Tyson et al. 1984). In nimodipine pre-treated 
animals CBF was preserved above this level in parts of the 
cerebral cortex (the peripheral and penumbral areas of the 
lesion); this is consistent with the neuropathological observ­
ation that none of the nimodipine pre-treated animals had 
ischaemic lesion as large as seen in some of the control rats.
On the other hand, the lack of effect of the drug upon pro­
foundly ischaemic tissue in the neostriatum explains the 
observation that the ischaemic damage was not ameliorated in 
all animals.
One major finding of this study is that the effects of 
nimodipine are less pronounced when assessed by volumetric 
analysis of ischaemic damage than when assessed as individual 
levels of CBF at corresponding sites within the lesion.
Various technical and biological explanations for the lack
of precise matching of the volume of ischaemic flow thresholds 
are possible: these include the necessity for performing the
two studies in separate parallel groups with dissimilar time 
constants, the single time point of the CBF measurements relat­
ive to the drug dosage over the first hour and the possibility 
that CBF thresholds for ischaemic damage might vary in differ­
ent brain regions.
Previous studies on the effects of various calcium antag­
onists on cerebral ischaemic lesion are summarised in Table 33.
It can readily be seen that these studies have employed differ­
ent species, different lesions, different drugs and different 
schedules of administration. Moreover, different methods have 
been used to measure CBF, and also to assess the severity of 
the ischaemic brain damage. It is therefore not surprising 
that the results are conflicting! The calcium antagonist, 
flunarizine, has been reported to be a potent inhibitor of 
calcium-induced constriction of isolated arteries, being most 
effective in cerebral artery (van Neuten and Vanhoutte, 1981). 
Recently, White et al. (1982) reported that flunarizine not 
only improved but even increased cerebral cortical blood flow 
above pre-ischaemic level for 90 minutes following a 20 minute 
period of circulatory arrest in dog maintained on cardio­
pulmonary bypass. By contrast, Newberg et al. (1984) demon­
strated that flunarizine failed to improve the post-ischaemic 
CBF and the neurological outcome, this in agreement with 
Hossmann et al. (1983) who reported the failure of this drug 
to prevent post-ischaemic accumulation of calcium or to improve 
cortical electrical function or biochemical recovery.
The studies that are most relevant to the present experi­
ments were reported by Harris et al. (1982) and Reedy et al. (1983).
In both, the ischaemic lesion was produced by occlusion of the 
middle cerebral artery, and also in both, the animals were pre­
treated with calcium antagonist. Harris et al. (1982), like 
the present investigation, used nimodipine and observed that 
CBF was higher in treated animals, but reported that oedema 
was increased and calcium/potassium homeostasis was disturbed 
in nimodipine treated animals. They therefore doubted that 
nimodipine pre-treatment would result in overall benefits.
If nimodipine enhances tissue perfusion in regions which are 
irreversibly damaged, then these cerebral circulatory changes 
may not be of any therapeutic benefit because of the risks of 
oedema (Harris et al. 1982). However, it is important to note 
that Harris et al. (1982) utilised hypotension in addition to 
occlusion in order to produce their lesion; this additional 
insult would have produced other systemic effects, such as 
hyperglycaemia and elevation of circulating catecholamines, so 
these would be likely to exacerbate the tissue effects of 
ischaemia (Siemkowicz and hansen, 1978; Pulsinelli et al.
1982a). In the present study, conditions were carefully 
controlled and there were minimal variations in arterial blood 
pressure (a maximum reduction of 8% with nimodipine 1 jig kg  ^
min ^ pre-treatment) or in PaCO^, PaO^ or arterial blood glucose.
Reedy et al. (1983) were unable to observe an effect upon 
CBF in animals treated with a calcium antagonist. They used 
verapamil, a weaker agent (Towart et al. 1982; Andersson et al.
1983), in a dose that may have been inadequate.
Beneficial effects on ischaemic brain damage, as judged 
either by neurological outcome, survival, or electrophysiolog- 
ical parameters, have been reported after either pre-treatment 
with nimodipine (Hoffmeister et al. 1979; Steen et al. 1983)
or post-treatment (Gelmers, 1984; Steen et al. 1984). Smith 
et al. (1983) have reported on the lack of benefit from nimod­
ipine in terms of the EEG after pre-treatment of global ischaemia. 
Other reports of lack of benefit of calcium antagonists upon 
tissue calcium content, and upon the neuropathological signs 
of ischaemic damage (Hossmann et al. 1983; Reedy et al. 1983), 
concern.either verapamil (Reedy et al. 1983), in a dose that 
did not affect CBF, flunarizine post-treatment (Hossmann et al. 
1983; Newberg et al. 1984) or lidoflazine (Dean et al. 1984).
Despite the differences in ischaemic model, agent, and 
method of administration, the most critical factor in determin­
ing the effects- of a calcium antagonist upon an ischaemic insult 
may be the stage that treatment is instituted. The study prov­
ides convincing experimental evidence that pre-treatment with 
nimodipine could have beneficial effects in improving blood 
flow and in limiting cerebral damage in areas of brain adjacent 
to the "core" of a focal ischaemic lesion. However, nimodipine 
failed to modify the CBF pattern when given after the ischaemic 
insult. Pre-treatment with a calcium antagonist, therefore, 
may be most useful clinically in patients identified to be at 
risk of developing focal ischaemia, rather than in the treat­
ment of established lesions.
There is already some clinical evidence that prophylactic 
treatment with nimodipine may be beneficial in prevention of 
ischaemia deficits due to "vasospasm" resulting from subarach­
noid haemorrhage (Allen et al. 1983). The findings of the 
present study are therefore of considerable relevance to patients 
with subarachnoid haemorrhage and patients with warning symptoms 
of occlusive cerebrovascular disease.
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Figure 26.
The frequency distribution of hemispheric blood flow 
(at the level of sensory motor cortex)
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CUM ULATIVE  CBF (ml 1 0 0 g m ^ m in ^ )
Data are presented as mean area (55) + SE, with cumulative CBF 
values within each flow bin: 0-25■, 0-50, 0-75, .... 0-300 ml
100g-^min~^ for hemispheric blood flow; contralateral (vehicle, 
n-5) compared with contralateral (nimodipine, n=5).
*p<0.05; **p<0.01 and #* * p < 0.001. Student's unpaired
t-test.
Figure 27.
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The frequency distribution of hemispheric blood flow 
(at the level of sensory motor cortex)
Vehicle
Nimodipine
50 100 150 200 250
CUMULATIVE CBF (ml 100gm^min^)
Data are presented as mean area (%) + SE, with cumulative CBF 
values within each flow bin: 0-25, 0-50, 0-75 .... 0-300 ml 
100g”^min ^ for hemispheric blood flow; ipsilateral (vehicle, 
n=5) compared with ipsilateral (nimodipine, n=5).
*p<0.05; **p<0.01 (Student's unpaired t-test).
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APPENDIX II
Errors associated with optical 
density measurements.
The blood samples data, including the time, the radio­
activity concentration and the weight of each sample is 
stored in the computer, and the CBF programme is carried 
out. The optical densities which correspond to flows of 
50, 100, 150 ... 400 are obtained. The corresponding 
optical density within a value of + 10% to each blood flow 
level is calculated. These steps are performed for Models 
A, B and C when the isotope is infused over 30 or 60 second 
periods (see Tables 18-23).
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APPENDIX III
Errors associated with underestimation 
of the tracer concentrations.
The blood samples data, sample time and the weight of 
each blood sample is stored in the computer. The CBF pro­
gramme is run to give the corresponding concentration of 
each sample. The 1%, 5% and 10% concentration of each 
sample is calculated (for example see Table 24). By using 
another CBF programme the new blood flows, compared to those 
of the base line data, are calculated by knowing the time and 
the corresponding concentrations of the tracer for each sample. 
The CBF values for Models A, B and C within a value of -1%,
-5% or -10% of underestimation of the tracer concentration 
are shown in Tables 24-30.
TABLE 24. BLOOD DATA AND SAMPLE TIME OF CBF. 
(MODEL A: 30 SEC).
Time 
(Min)
Concen­ Concen­ Concen­ Concen­
Sample tration tration tration tration
Base line -1% -5% -10%
1 0.00 0.0 0 0 0
2 0.07 283.8 280.9 269.6 255.4
3 0.09 378.4 374.6 359.4 340.5
4 0.12 473.0 468.2 449.3 425.7
5 0.17 662.2 655.5 629.1 595.9
6 0.19 756.8 749.2 718.9 681.1
7 0.22 851.4 842.8 808.8 766.2
8 0.24' 945.9 936.4 898.6 851.3
9 0.27 1040.5 1030.1 988.4 936.4
10 0.29 1135.1 1123.7 1078.3 1021.6
11 0.32 1229.7 1217.4 1168.2 1106.7
12 0.34 1324.3 1311.1 1258.1 1191.8
13 0.37 1418.9 1404.7 1347.9 1277.0
14 0.39 1513.5 1498.3 1437.8 1362.1
15 0.42 1608.1 1591.9 1527.6 1447.2
16 0.44 1664.9 1648.2 1581.6 1498.4
17 0.47 1731.1 1713.7 1644.5 1557.9
Concentration
(nCi/ml)
1770.8 1735.5 1665.5 1577.7
C-Iodoantipyrine blood sample concentration involved errors 
produced by the liquid scintillation analyser within a value 
of -1%, -5% or -10%. Kill-time = 0.48 min; catheter flow 
= 2.6 ml/min, and catheter lag-time = 0.01 min.
TABLE 25.
14C-I0D0ANTIPYRINE UNDERESTIMATION AND RELATIONSHIP
TO THE CBF (MODEL A: 30 SEC).
CBF 
Base line
CBF
-1%
CBF
-5%
CBF
-10%
50 51 54 57
100 102 107 115
• 150 154 163 176
200 205 219 238
250 258 276 304
300 310 328 374
350 363 395 446
400 415 475 523
CBF (ml lOOg ^min levels related to underestimation
produced by liquid scintillation analyser within a value
14of -1%, -5% or -10% in the C-iodoantipyrine concentration.
TABLE 26.
14C-I0D0ANTIPYRINE UNDERESTIMATION AND RELATIONSHIP
TO THE CBF (MODEL A: 60 SEC).
CBF 
Base line
CBF
-1%
CBF
-5%
CBF
-10%
50 51 53 57
100 101 108 118
150 153 166 185
200 205 226 266
250 257 290 346
300 311 356 444
350 362 428 562
400 419 509 . 706
- 1 - 1CBF (ml lOOg min ) levels related to underestimation produced 
by liquid scintillation analyser within a value of -1%, -5% or 
-10% in the ^4C-iodoantipyrine concentration.
TABLE 27.
14c-iod oan t i p y r i n e UNDERESTIMATION AND RELATIONSHIP
TO THE CBF (MODEL B: 30 SEC).
CBF 
Base line
CBF
-1%
CBF
-5%
CBF
-10%
50 54 56 59
100 108 114 121
150 163 172 184
200 219 231 248
250 ' • 275 291 314
300 334 354 383
350 391 416 451
400 449 479 522
CBF (ml lOOg ^min levels related to underestimation
produced by liquid scintillation analyser within a value
14
of -1%, -5% or -10% in the C-iodoantipyrine concentration.
TABLE 28.
14C-I0D0ANTIPYRINE UNDERESTIMATION AND RELATIONSHIP
TO THE CBF (MODEL B: 60 SEC).
CBF 
Base line 1 
o
m 
to CBF
-5%
CBF
-10%
50 52 54 58
100 105 110 118
150 158 167 181
200 213 226 246
250 267 285 311
300 323 345 379
350 381 408 450
400 436 469 518
-1 -1
CBF (ml lOOg min ) levels related to underestimation
produced by liquid scintillation analyser within a value
14
of -1%, -5% or -10% in the C-iodoantipyrine concentration.
TABLE 29.
14c-i od oant ipyri ne UNDERESTIMATION AND RELATIONSHIP
TO THE CBF (MODEL C: 30 SEC).
CBF 
Base line
CBF
-1%
CBF
-5%
CBF
-10%
50 51 54 57
100 101 107 116
150 153 164 179
200 205 221 246
250 257 282 323
300 309 345 409
350 362 414 525
400 416 495 712
CBF (ml lOOg ^min levels related to underestimation
produced by liquid scintillation analyser within a value
14
of -1%, -5% or -10% in the C-iodoantipyrine concentration.
TABLE 30.
14c-iodoant ipyri ne UNDERESTIMATION AND RELATIONSHIP
TO CBF (MODEL C: 60 SEC).
CBF 
Base line
CBF
-1%
CBF
-5%
CBF
-10%
50 51 56 60
100 101 109 122
150 155 172 266
200 210 250 370
250 264 358 -
300 327 664 -
350 398 - -
400 481 - -
CBF (ml lOOg ^min levels related to underestimation
produced by liquid scintillation analyser within a value
14
of -1%, -5% or -10% in the C-iodoantipyrine concentration. 
(- indicates the failure of computer to convert the new 
blood flow.value).
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